CALGB Publications

Table 10

Group Bibliography, Published, 1/1/1995 - 5/31/2006

7521
A controlled trial of chemoimmunotherapy of acute myelogenous leukemia with the methanol extraction residue of tubercle bacilli (MER)
Cattner J, Gildewell O, Holland JF
In Immunotherapy of Human Cancer, Terry/Rosenberg (ed.) Elsevier North Holland, Inc., , 1999Published Date 8/20/1999

7551
Augmented therapy of extensive Hodgkin’s disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival—results of a Cancer and Leukemia Group B study

7581
The >20-year natural history of node-positive primary breast carcinoma treated with CMF-based adjuvant chemotherapy: A Study by the Cancer and Leukemia Group B
Journal of Clinical Oncology 21(9):1825-1835, 2003 Published Date 5/1/2003

7581
The natural history of node-positive primary breast cancer treated with CMF-based adjuvant therapy
Weiss RB, Cirrincione CT, Demakos E, Holland JF, Falkson G, Robbins A, Bothun S, Berry DA, Henderson IC
Anti-Cancer Drugs 6(2):87, 1995 Published Date 1/1/1995

7611
A comparative study of the long-term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation
Cancer 82:208-218, 1998 Published Date 2/1/1998

7951
Single agent versus combination chemotherapy in follicular, low grade lymphomas. A study of the Cancer and Leukemia Group B
Peterson BA, Petroni GR, Frizzera G, Barcos MP, Bloomfield CD, Nissen N, Hurd DD, Henderson E, Sartiano GP, Johnson JL, Holland JF, Gottlieb A
Journal of Clinical Oncology 21(1):5-15, 2003 Published Date 1/1/2003

7951
Second malignancies in patients with follicular, low grade lymphomas. An analysis of CALGB 7951
Petroni GR, Johnson JL, Barcos M, Peterson BA
Proc ASCO 15: 418, 1996 Published Date 1/1/1996

8082
Association of Angiogenesis in Lymph Node Metastases with Outcome of Breast Cancer

8082
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a noncross-resistant regimen: a CALGB study
J Clin Oncol,14 (5):1589-1598, 1996 Published Date 1/1/1996

8082
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer: a Cancer and Leukemia Group B study
J Natl Cancer Inst 88:661-667, 1996 Published Date 1/1/1996
Thoracic radiation therapy added to chemotherapy for small cell lung cancer: An update of Cancer and Leukemia Group B study 8083

Perry MC, Herndon JE, Eaton WL, Green MR

Journal of Clinical Oncology 16(7):2466-2467, 1998

Published Date 7/10/1998

Thoracic radiation therapy added to chemotherapy for small cell lung cancer: An update of Cancer and Leukemia Group B study 8083

Perry, Herndon JE, Eaton W, Green MR

Proc ASCO 15:384, 1996

Published Date 1/1/1996

Combination chemotherapy for metastatic or recurrent carcinoma of the breast–A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: CALGB # 8281


Published Date 1/1/1995

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection - Cancer and Leukemia Group B Study 8361


Blood 97:3574-3580, 2001

Published Date 6/1/2001

Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia: FAB-M6): a CALGB study

Davey FR, Abraham N, Brunetto VL, Maccallum JM, Nelson DA, Ball ED, Griffin JD, Baer MR, Wurster-Hill D, Mayer RJ, Schiffer CA, Bloomfield CD


Published Date 1/1/1995

High frequency of change in immunophenotype of acute myeloid leukemia at first relapse demonstrated by multiparameter flow cytometry

Baer MR, Stewart CC, Yosuico V, Lawrence D, Arthur D, Bloomfield CD

Blood 86 (10): 332a, 1995

Published Date 1/1/1995

Multiparameter flow cytometry (MFC) analysis of de novo acute myeloid leukemia (AML) reveals low frequencies of lymphoid antigen expressions and strong associations between immunophenotype and karyotype

Baer MR, Stewart CC, Lawrence D, Powell B, Schiffer CA, Davey FR, Arthur DC, Bloomfield CD

Blood 86 (10): 266a, 1995

Published Date 1/1/1995

Value of immunophenotype (IP) in intensively treated adult acute lymphoblastic leukemia (ALL): CALGB 8364

Frankel SR, Stewart CC, Dodge R, Davey F, Larson RA, Szatrowski TP, Schiffer CA, Bloomfield CD

Blood 86 (10): 173a, 1995

Published Date 1/1/1995

Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial

Dillman RO, Herndon JE, Seagren SL, Eaton WL, Green MR


Published Date 1/1/1996
8461 Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): results from Cancer and Leukemia Group B study 8461
Journal of Clinical Oncology 23(24):5705-5717, 2005
Published Date 8/20/2005

8461 Comparison of pretreatment characteristics and outcome of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations involving 11q23
Blum WG, Mrozek KA, Maharry KS, Raimondi SC, Carroll AJ, Larson RA, Rowley JD, Bloomfield CD
Proc ASCO:6549, 2005
Published Date 5/16/2005

8461 Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: CALGB 8461
Journal of Clinical Oncology 23(3):482-493, 2005
Published Date 1/20/2005

8461 Early allogeneic transplantation should be considered for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from CALGB 8461 and review of the literature
Cancer 101:1420-1427, 2004
Published Date 12/25/2004

8461 t(8;21) acute myeloid leukemia (AML) differs from inv(16) AML in pretreatment characteristics, outcome and prognostic factors predicting outcome: a Cancer and Leukemia Group B study
Blood 104(11):2017, 2004
Published Date 12/1/2004

8461 Central review of cytogenetics is essential for cooperative group clinical and correlative studies of acute leukemia: the Cancer and Leukemia Group B (CALGB) 8461 experience
Blood 104(11):1081, 2004
Published Date 12/1/2004

8461 Acute myeloid leukemia (AML) with t(6;9)(p23;q24) defines a very poor risk subtype of leukemia with distinguishing clinical-pathological features: a US cytogenetics intergroup study of 62 t(6;9) AML cases
Blood 104(11):567, 2004
Published Date 12/1/2004

8461 Pre-treatment cytogenetics predict complete remission and long-term outcome in patients over 60 years with acute myeloid leukemia: results from CALGB 8461
Blood 104(11):568, 2004
Published Date 12/1/2004

8461 Core binding factor in adult acute myeloid leukemia (AML)
Annals of Hematology 83:S84-85, 2004
Published Date 7/4/2004

8461 Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461
Journal of Clinical Oncology 22(12):2410-2418, 2004
Published Date 6/15/2004

8461 Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): results from Cancer and Leukemia Group B (CALGB) 8461
Proc ASCO:6514, 2004
Published Date 5/1/2004

8461 Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from CALGB 8461
Proc ASCO:6543, 2004
Published Date 5/1/2004
8461 Repetitive cycles of high-dose cytarabine may decrease cumulative incidence of relapse in patients with inv(16)(p13q22) or t(16;16)(p13;q22): results from Cancer and Leukemia Group B (8461)
Journal of Clinical Oncology 22(6):1087-1094, 2004
Published Date 3/15/2004

8461 Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML)

8461 Secondary Chromosome Aberrations in Adult Acute Lymphoblastic Leukemia (ALL) with t(9;22)
Blood 98 (Suppl 1):466, 2001
Published Date 11/1/2001

8461 Abnormal Karyotype during Complete Remission Predicts Short Relapse-Free Survival (RFS) in Acute Myeloid Leukemia (AML)
Blood 98 (Suppl 1):2421, 2001
Published Date 11/1/2001

8461 Pre-Treatment Cytogenetics Predict Initial Induction Success and Overall Survival in Adult Patients with De Novo Acute Myeloid Leukemia
Published Date 11/1/2001

8461 Trisomy as an isolated cytogenetic abnormality is an adverse prognostic factor in patients with acute myeloid leukemia (AML) - results from CALGB 8461
Proc ASCO 20:282a (#1124), 2001
Published Date 5/1/2001

8461 Karyotype change in adult acute myeloid leukemia (AML) at first relapse
Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Larson RA, Bloomfield CD
Blood 96 (Suppl 1):706a (#3046), 2000
Published Date 4/1/2000

8461 Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
Journal of Clinical Oncology 17(12):3767-3775, 1999
Published Date 12/15/1999

8461 Adult AML patients with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered
Bloomfield CD
Annals of Hematology 78 (suppl II):S13, 1999
Published Date 11/11/1999

8461 Adult acute myeloid leukemia (AML) patients (pts) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered
Blood 92(10) Suppl:#1282, 1998
Published Date 11/15/1998

8461 Trisomy 8 represents a poor risk group in adult acute lymphoblastic leukemia (ALL)—Results from CALGB 8461
Wetzler M, Dodge RK, Mrozek KA, Carroll AJ, Larson RA, Bloomfield CD
Blood 91 (Suppl 1):223a #914, 1998
Published Date 11/15/1998

8461 t(9;11)(p22;q23) confers better prognosis that other translocations of 11q23 in adults with de novo acute myeloid leukemia (AML)
Mrozek KA, Heimonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Schiffer CA, Bloomfield CD
Cytogeten Cell Genet. 77:136, 1997
Published Date 6/22/1997

8461 Isochromosome 12p in two cases of acute myeloid leukemia without evidence of germ cell tumor
KH, PK, JL, SJC, CD B, KMM
Published Date 1/1/1996

8461 Acute myeloid leukemia (AML) patients with pre-treatment isolated trisomy 8 are a poor prognostic group who are rarely cured with chemotherapy: results of CALGB 8461
Byrd JC, Lawrence D, Arthur DC, Davey F, Schiffer CA, Bloomfield CD
Published Date 1/1/1996
Rearrangement of ALL1 in adult acute myeloid leukemia (AML) with normal cytogenetics is a recurrent molecular defect that predicts a short complete remission (CR) duration.

Proc ASCO 15:360, 1996

Secondary cytogenetic changes in acute promyelocytic leukemia (APL): prognostic importance and association with the intron 3 breakpoint of the promyelocytic leukemia (PML) gene


Trisomy 11 as the sole karyotypic abnormality identifies a group of older patients with acute myeloid leukemia (AML) with FAB M2 or M1 and unfavorable clinical outcome: results of CALGB 8461


Der(16)(1;16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia chromosome-positive acute lymphoblastic leukemia

Int J Oncol 6:531-538, 1995

Extradematullary leukemia (EML) is associated with pre-treatment cytogenetic abnormalities in patients with acute myeloid leukemia (AML)

Blood 86 (10):43a, 1995

Power calculations for mixture models in survival

Lawrence DD, Priore RL, George SL

The partial tandem duplication of ALL1 as a recurrent novel molecular defect in acute myeloid leukemia (AML) with trisomy 11

Strout MP, Caligiuri MA, Schichman SA, Mrozek K, Herzig GP, Arthur DC, Heinonen K, Knuutila S, Nousiainen T, Ruaru T, Block AW, Croce CM, Bloomfield CD
Blood 86 (10):429a, 1995

Patients with acute myeloid leukemia (AML) and mutant RAS proto-oncogenes benefit from intensification with high-dose cytarabine (HDAC): results from the randomized Cancer and Leukemia Group B (CALGB) 8525 study

Proc ASCO:6514, 2005

Intensified post-remission chemotherapy for adults with AML: an update of CALGB 8525

Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Shulman P, Omura GA, Moore GO, McIntyre OR, Frei III E
Leukemia Symposium, 1995

Accepted Date 1/1/1995

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited stage small cell lung cancer: CALGB protocol 8534: A Cancer and Leukemia Group B Study


Psychological and neuropsychological functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin, for Cancer and Leukemia Group B, study 8534


Published Date 5/1/1998
A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome
Dressler LG, Broadwater G, Berry DA, Cirrincione CT, Cowan D, Harris LN, Moore D, Mass HB, Hayes DF, Ellis MJ
Proc ASCO:566, 2004
Published Date 5/1/2004

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
Published Date 8/19/1998

Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541
Roach MR, Cirrincione CT, Budman DR, Hayes DF, Berry DA, Younger J, Hart R, Henderson IC
Published Date 4/18/1997

The relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer (CALGB 8541)
Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL
Published Date 1/1/1996

The relationship between toxicity and obesity in adjuvant therapy for breast cancer (CALGB 8541)
Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL
Proc ASCO 14:111, 1995
Published Date 1/1/1995

Alternating Chemotherapy Regimens for Patients With Metastatic Breast Cancer--A Pilot Study Based on Tumor Marker Kinetics
Cancer 75 (3):826-830, 1995
Published Date 2/1/1995

Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B
Rai KR, Davey F, Peterson B, Schiffier C, Silver RT, Ozer H, Golomb H, Bloomfield CD
Leukemia 9(7):1116-1120, 1995
Published Date 1/1/1995

A Phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: A Cancer and Leukemia Group B study
Published Date 1/1/1996

Induction chemoradiation followed by surgery in stage IIA non-small cell carcinoma of the lung (NSCLC): long term results of Cancer and Leukemia Group B protocol 8634
Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Green MR
Proc ASCO 15: 376, 1996
Published Date 1/1/1996

Safety and Efficacy of Using a Single Agent Or a phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study: CALGB 8642
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione CT, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL
Journal of Clinical Oncology 17(5):1397-1406, 1999
Published Date 5/1/1999

Amonafide: an active agent in the treatment of previously untreated advanced breast cancer: a Cancer and Leukemia Group B Study (CALGB 8642)
Costanza ME, Berry DA, Henderson IC, Ratain MJ, Wu KP, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss A
Published Date 1/1/1995

A randomized comparison of single agent induction chemotherapy vs. standard chemotherapy for stage IV breast cancer: CALGB 8642
Costanza ME, Henderson IC, Berry D, Cirrincione C, Frei E, McIntyre OR, Weiss RB
Proc ASCO 14:116, 1995
Published Date 1/1/1995
Risk of adult leukemia in relation to prior immune-related conditions

Cooper GS, Kamel, Sandler DP, Davey FR, Bloomfield CD
Ca Epid, Biomarkers & Prev 5:867-872, 1996
Published Date 11/1/1996

Carcinogen metabolism polymorphism and myelodysplastic syndrome

Proc Am Assoc Ca Res 36:133, 1995
Published Date 1/1/1995

Exposure to chemicals and risk for myelodysplastic syndrome (MDS)

Sandler DP, Shore DL, Liu E, Bloomfield CD
Am J Epidemiol S60:141, 1995
Published Date 1/1/1995

Circulating HER2/c-neu extra cellular domain (ECD/HER2) as a prognostic factor in patients with metastatic breast cancer: A Cancer and Leukemia Group B study

Hayes DF, Yamauchi H, Broadwater GJ, Cirrincione CT, Carney W, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC
Clinical Cancer Research 7:2703-2711, 2001
Published Date 9/5/2001

A Prognostic Model for Low-Grade Follicular Non-Hodgkin’s Lymphoma

Seng JE, Petroni GR, Oken MM, Barcos MP, Peterson BA
Proc ASCO 17:10a-35, 1998
Published Date 5/15/1998

Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486)

Peterson BA, Petroni GR, Oken MM, Johnson JL, Barcos MP, Cooper MR
Proc ASCO 16:14a, 1997
Published Date 5/1/1997

Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: Ten-year analysis. An Intergroup Study

Mansour EG, Gray R, Shatila AH, Tourmey DC, Cooper MR, Osborne CK, Falkson G
Published Date 11/1/1998

MOPP/ABV Hybrid Chemotherapy for Advanced Hodgkin’s Disease Significantly Improves Failure-Free and Overall Survival: The 8-Year Results of the Intergroup Trial

Glick JH, Young ML, Harrington DP, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM
Published Date 1/15/1998

An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by the Cancer and Leukemia Group B

Lee EJ, George SL, Amrein PC, Paciucci PA, Allen SL, Schiffer CA
Leukemia 12(3):139-143, 1998
Published Date 2/1/1998
A phase II study of recombinant interferon-gamma as maintenance therapy following combination chemotherapy for patients with extensive small cell lung cancer

Bitran J, Green M, Perry M, Hollis DR, Herndon JE


Dose Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741


Journal of Clinical Oncology 17(1):64-73, 1999

Prevalence of HTLV-I associated T-Cell Lymphoma


Blood molecular analysis is highly correlated to bone marrow cytogenetics as a biologic endpoint in chronic myelogenous leukemia (cml):

Stock W, Westbrook CA, Peterson B, Szatrowski TP, Silver RT, Arthur DC, Schiffer CA, Bloomfield CD

Proc ASCO 14: 429, 1995

Quantitative molecular monitoring of BCR/ABL transcripts in adult acute lymphoblastic leukemia (ALL) using a real-time PCR assay: pilot study from the Cancer and Leukemia Group B (CALGB 8762)

Stock W, Sher D, Dodge RK, Caligiuri M, Frankel S, Larson RA, Bloomfield CD

Blood 93(suppl 1):287a (#1281), 1999

PCR monitoring of minimal residual disease identifies good outcome in bcr/abl positive acute lymphoblastic leukemia (ALL): CALGB 8762


Blood 88 (10):477a, 1996

Low incidence of TAL1 gene rearrangements in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762)


High incidence of p16 deletion in adult acute lymphoblastic leukemia (ALL): Correlation with clinical features and response to treatment: CALGB 8762


Blood 86 (10): 268a, 1995
Five year follow-up of high dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving > 10 axillary lymph nodes (Duke/CALGB 8782)

Proc ASCO 14:317, 1995
Published Date 1/1/1995

Randomized comparison of pentostatin versus interferon alpha-2a in previously untreated patients with hairy cell leukemia: an intergroup study

Published Date 1/1/1995

Hypersensitivity reactions to L-Asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia

Larson RA, Fretzin MH, Dodge RK, Schiffer CA
Published Date 5/1/1998

Phase I trial of Etoposide, Carboplatin, and GM-CSF in Extensive Small-Cell Lung Cancer. A Cancer and Leukemia Group B study (CALGB 8832)

Luikart SD, Herndon JE, Hollis DR, McDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR
Published Date 2/1/1997

Dihydro-5 Azacytadine in Malignant Mesothelioma: A Phase II Trial Demonstrating Activity by Cardiac Toxicity

Published Date 11/1/1997

Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer, a phase II trial

Clamon G, Herndon JE, Akerley W, Green M
Published Date 2/28/1998

Long term survival data from CALGB 8837: Radiation dose escalation and concurrent chemotherapy (CT) in Limited Stage Small Cell Lung Cancer (LD-SCLC). Possible dose-survival relationship for total radiation dose and dose intensity

Choi NC, Herndon JE, Rosenman J, Carey R, Chung CT, Bogart J, Seagren S, Green MR
Proc ASCO 21:1190, 2002
Published Date 5/2/2002

Phase I study to determine the maximum tolerated dose (MTD) of radiation in standard daily and hyperfractionated-accelerated twice daily radiation schedules with concurrent chemotherapy for limited stage small cell lung cancer (Cancer and Leukemia Group B 8837)

Published Date 11/1/1998

Phase I study to determine the maximum tolerated dose (mtd) of radiation in standard daily (qd) and accelerated twice daily (bid) radiation schedules with concurrent chemotherapy (ct) for limited stage small cell lung cancer: CALGB 8837

Choi NC, Herndon J, Rosenman J, Carey R, Chung CT, Bernard S, Leone L, Seagren S, Green M
Proc ASCO 14: 363, 1995
Published Date 1/1/1995
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide (CHOPE) for advanced stage Hodgkin’s Disease: CALGB 8856

Lester EP, Petroni GR, Barsoc MP, Johnson JL, Millard F, Cooper MR, Omura GA, III EF, Peterson BA
Cancer Investigation 19(5):447-458, 2001 Published Date 7/16/2001

CALGB 8856: a phase II study of CHOPE (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) for advanced stage Hodgkin’s disease: an analysis of cohort II
Lester EP, Petroni GR, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, Peterson BA
Proc ASCO 15: 416, 1996 Published Date 1/1/1996

CHOPE (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) for advanced stage Hodgkin’s disease (HD), a Phase II study: CALGB 8856
Lester EP, Petroni GR, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, Peterson BA
VI International Conference on Malignant Lymphoma Lugana, 1996 Published Date 1/1/1996

CHOPE [cyclophosphamide (c), doxorubicin (h), vincristine (o), prednisone (p) and etoposide (e)] followed by ABVD for advanced stage Hodgkin disease (HD), a phase II study: CALGB 8856
Lester EP, Petroni GR, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, Peterson BA
Proc ASCO 14: 391, 1995 Published Date 1/1/1995

Association of angiogenesis in lymph node metastases with outcome of breast cancer

Population pharmacodynamic study of amonafide: Cancer and Leukemia Group B 8862
J Clin Oncol 13(3):741-747, 1995 Published Date 1/1/1995

Flow cytometry analysis in node positive breast cancer with emphasis on standardization and clinical outcome: A companion trial of the Cancer and Leukemia Group B.
Kate T E, Quadri Y, Mass H, Zbieranski N, Cirrincione C, Barsco M, Thor A, Koerner F, Henderson IC
Communications in Clinical Cytometry, 22: 297-306, 1995 Published Date 1/1/1995

Autologous bone marrow transplantation (ABMT) in acute myeloid leukemia (AML) at relapse using monoclonal antibody-purged bone marrow: CALGB study 8882
Mills LE, Ball ED, Rybka W, Hurd DD, Gingrich R, Rosner GL, Schiffer C
Blood 86 (Suppl): 959a, 1995 Published Date 1/1/1995

Radiation Therapy Quality Control in a Clinical Trial of Adjuvant Postoperative Treatment for Rectal Cancer
Int J Radiation Oncology Biol Phys 32(1): 51-55, 1995 Published Date 1/1/1995
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes: Intergroup 0089
Berger AC, Sigurdson E, LeVoyer T, Hanlon A, Mayer RJ, MacDonald JS, Catalano PJ, Haller D
Journal of Clinical Oncology 23(34):8706-8712, 2005

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ
Journal of Clinical Oncology 23(34):8671-8678, 2005

Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer
McCullum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS

Surveillance for Second Primary Colorectal Cancer after Adjuvant Chemotherapy: An Analysis of Intergroup 0089
Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, Haller DG
Annals of Internal Medicine 136 No. 4:261-269, 2002

Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089
Haller DG, Catalano PJ, MacDonald J, Mayer R
Proc ASCO 17:256a-982, 1998

Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089
Haller DG, Catalano PJ, MacDonald J, Mayer R
Proc ASCO 16:265a, 1997

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
O’Connell MJ, Mailliard JA, Kahn MJ, MacDonald JS, Haller DG, Mayer RJ, Wieand HS

Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089
Haller DG, Catalano PJ, MacDonald JS, Mayer R
Proc ASCO 15:211, 1996

Gender as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer
Haller DG, Catalano P, MacDonald JS, Mayer RJ, Hodi FS
Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, 1995
Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, 1995

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102
Journal of Clinical Oncology 23 (33):8313-8321, 2005

CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results
22nd Annual San Antonio Breast Cancer Symposium: #1, 1999

CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT 0102.
Proc ASCO 17:1a #2, 1998

Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup studies.
Subcutaneous azacytidine compared to supportive care in Patients with myelodysplastic syndrome: A Cancer and Leukemia Group B study
Cancer Invest 17(suppl) 1:4 (#5), 1999

Post-remission therapy in older patients with de novo acute myeloid leukemia (AML): A randomized trial of mitoxantrone/intermediate dose cytarabine ‘versus’ standard dose cytarabine (CALGB study 8923)
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Bloomfield CD, Schiffer CA
Blood 98:548-553, 2001

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA

Is Quality of Life Predictive of Survival Among Patients with Advanced Non-Small Cell Lung Carcinoma?
Herdon JE, Fleishman S, Kornblith AB, Kosty MP, Green MR, Holland JC

A longitudinal study of quality of life in advanced non-small cell lung cancer: CALGB 8931
Herdon JE, Fleishman S, Kosty MP, Green MR
Control Clin Trials 18:286-300, 1997

A randomized trial of hydrazine sulfate in advanced non-small cell lung cancer: CALGB 8931
Herdon JE II, Fleishman S, Kosty M, Green M
American Statistical Association, 1-9, 1995

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study

Kumar P, Herndon JE, Sugarbaker DJ, Kohman LJ, Elias AD, Green MR
Proc ASCO 19:496a-1939, 2000

N2 status at resection predicts long-term outcome following induction therapy for stage IIIA non-small cell lung cancer: CALGB 8935
Sugarbaker DJ, Herndon JE, DeCamp MM, Jaklitsch MT, Richards W, Kumar P, Green MR

Patterns of disease failure following tri-modality therapy in pathologically staged IIA (N2) non-small cell lung cancer: analysis of Cancer and Leukemia Group B protocol 8935

Results of Cancer and Leukemia Group B Protocol 8935: A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer
Patterns of relapse following tri-modality treatment in patients with pathologically staged IIIA (N2) non-small cell lung cancer (NSCLC): analysis of Cancer and Leukemia Group B (CALGB) Protocol 8935
Proc American Radium Society, p. 31, 1995

High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of the Cancer and Leukemia Group B (CALGB)
Breast Cancer Research and Treatment 36: 35-40, 1995

A randomized comparison of ABVD vs MOPP/ABV for the treatment of advanced Hodgkin’s Disease: Report of an Intergroup Trial
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Peterson BA

MOPP/ABV vs ABVD for advanced Hodgkin’s disease: A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC)
Duggan DB, Petroni GR, Johnson JL, Hanson K, Glick JH, Connors JM, Cherry RC, Barcos MP, Peterson BA
Proc ASCO 16:12a, 1997

Long-term psychosocial adaptation of survivors of acute leukemia: a Cancer and Leukemia Group B quality of life study
Proc ASCO 14: 508, 1995

Megestrol acetate for the treatment of cachexia a dose-response trial in patients with advanced lung or colorectal cancers
Parnes H, Conaway MR, Aisner J, Potthoff RF, Kornblith AB, Cooper MR, Kirshner J, Davila E, Szatrowski TP, Ellerton J, Shea TC, Mortimer JE, Maurer LH, Vinciguerra V
Cancer Therapeutics 2:75-82, 1999

Sphincter sparing treatment for distal rectal adenocarcinoma
Steele GD, Herndon JE, Bleday R, Russell A, Benson AB, Hussain M, Burgess AM, Tepper JE, Mayer RJ
Annals of Surgical Oncology 6(5):443-441, 1999

Failure and Salvage After Sphincter-Sparing Treatment for Distal Rectal Adenocarcinoma—A CALGB Coordinated Intergroup Study
Steele GD, Tepper JE, Herndon JE, Mayer RJ
Proc ASCO 18:235A-903, 1999

Sphincter sparing treatment for distal rectal adenocarcinoma: a phase II Intergroup study
Steele GD, Herndon JE, Burgess AM, Bleday R, Russell A, Benson AB, Hussain M, Mayer RJ
Proc ASCO 16:256a, 1997

Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukemia Group B study
Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ
9011 Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Cancer Chemother Pharmacol 50:37-45, 2002
Published Date 9/28/2002

9011 Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study CALGB 9011
Journal of Clinical Oncology 20(18):3878-3884, 2002
Published Date 9/15/2002

9011 Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: an intergroup study (CALGB 9011)
Published Date 8/15/2001

9011 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
Published Date 12/14/2000

9011 Transformation to Richter’s Syndrome or prolymphocytic leukemia (PLL), and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL): An intergroup study (CALGB 9011)
Blood 94 (10) suppl 1:4013, 1999
Published Date 11/11/1999

9011 Therapy-Related Myelodysplastic Syndrome (T-MDS) or Acute Myeloid Leukemia (T-AML) in patients with Chronic Lymphocytic Leukemia (CLL) treated with Chlorambucil (C), Fludarabine (F), or Fludarabine + Chlorambucil (F+C): An Intergroup Study (Cancer and Leukemia Group B 9011)
Proc ASCO 18:9a–29, 1999
Published Date 5/15/1999

9011 The impact of therapy with chlorambucil (C), fludarabine (F) or fludarabine + chlorambucil (F+C) on infections in patients with chronic lymphocytic leukemia (CLL): an Intergroup Study (CALGB 9011)
Published Date 11/15/1998

9011 A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C, and ECOG Intergroup study.
Blood 88 (10):141a, 1996
Published Date 1/1/1996

9011 Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). a randomized intergroup study
Blood 86 (10): 607a, 1995
Published Date 1/1/1996

9013 Treatment of the chronic phase of CML with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: CALGB 9013
Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA
Published Date 1/3/2003

9013 Treatment of chronic myeloid leukemia (CML) with an intermittent schedule of interferon alfa-2B (rIFN- α) and cytarabine (ara-C): CALGB 9013
Silver RT, Peterson BL, Szatrowski TP, Powell BL, Bloomfield CD, Schiffer CA, Larson RA
Proc ASCO 20:1222, 2001
Published Date 5/1/2001

9013 Risk factors for severe neuropsychiatric toxicity in patients receiving Interferon-alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of Cancer and Leukemia Group B 9013
Hensley ML, Silver RT, Peterson BL, Larson RA, Szatrowski TP
Published Date 3/1/2000

9013 Risk factors for severe neuropsychiatric toxicity (NPtox) in patients receiving Interferon-Alfa-2b (rIFN- α) and low-dose cytarabine (AraC) for chronic myeloid leukemia (CML): Analysis of CALGB 9013
Hensley ML, Silver RT, Peterson BL, Larson RA, Szatrowski TP
Proc ASCO 18:415a–1604, 1999
Published Date 5/15/1999
Combined α-interferon (rIFNa-2b) and low dose cytosine arabinoside (Ara-C) for PH (+) chronic phase chronic myeloid leukemia (CML)
Blood 88 (10): 638a, 1996

A Phase III trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed or refractory acute myelogenous leukemia. CALGB 9021
Peterson B, George SL, Bhalla K, Lee E, Carpenter JT, Berk GI, Schiffer CA Proc ASCO, 1996

Granulocyte-colony stimulating factor (Filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022
Moore JO, Dodge RK, Amrein PC, Kolitz JE, Lee EJ, Powell BL, Godfrey SA, Robert F, Schiffer CA

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A Phase II study by the Cancer and Leukemia Group B
Cancer 82(8):1578-1584, 1998

The health-related quality of life in small-cell lung cancer patients: Results of a companion study to CALGB 9033
Naughton MJ, Shumaker SA, Herndon JE, Miller AA, Kornblith AB, Chao D
Quality of Life Research 11:235-248, 2002

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B (CALGB 9033)

Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer
Investigational New Drugs 22:83-89, 2004

Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin’s disease and unfavorable prognostic features: A phase II CALGB Study (9051)
Wasserman TH, Petroni GR, Millard F, Chung C, Barcos MP, Johnson JL, Canellos GP, Peterson BA
Cancer 86(8):1590-1595, 1999

Etoposide, Vinblastine, and Doxorubicin (EVA) chemotherapy plus subtotal nodal irradiation for early stage, high risk Hodgkin’s disease. CALGB 9051
Wasserman TH, Petroni G, Millard F, Chung C, Johnson JL, Canellos GP, Peterson B
Proc ASCO 15: 427, 1996

Published Date 1/1/1996
Published Date 1/1/1996
Published Date 2/1/1997
Published Date 4/15/1998
Published Date 9/27/2002
Published Date 1/1/1995
Published Date 8/1/2002
Published Date 10/15/1999
Published Date 1/1/1996
Pharmacology of 21-day Oral Etoposide Given in Combination with Intravenous Cisplatin in Patients with Extensive-Stage Small-Cell Lung Cancer: A Cancer and Leukemia Group B Study (CALGB 9062)
Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL
Clinical Cancer Research 3:719-725, 1997
Published 3/1/1997

Pharmacology of 21-day oral etoposide given in combination with intravenous cisplatin for extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 9062)
Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL
Proc ASCO 15: 472, 1996
Published Date 1/1/1996

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: A Cancer and Leukemia Group B study
Lung Cancer 21:203-211, 1998
Published Date 9/1/1998

Quality of life among patients w/stage II & III breast carcinoma randomized to receive high-dose chemotherapy w/ autologous bone marrow support or intermediate-dose chemotherapy
Cancer 104(8):1580-1589, 2005
Published Date 10/15/2005

Quality of Life in Patients with Breast Cancer Randomized to High Dose Chemotherapy with Bone Marrow Support vs. Intermediate Dose Chemotherapy: CALGB 9066 (Companion protocol to CALGB 9082)
Proc ASCO 18:412a–1593, 1999
Published Date 5/15/1999

Recruiting cancer patients to participate in motivating their relatives to quit smoking: a cancer control study of the Cancer and Leukemia Group B (CALGB 9072)
Schilling A, Conaway MR, Wingate PJ, Atkins JM, Berkowitz IM, Clamon GH, DiFino SM, Vinciguerra V
Published Date 1/15/1997

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
Journal of Clinical Oncology 22(10):1773-1775, 2004
Published Date 4/1/2004

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from INT-0114
Published Date 2/15/2004

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively-resected rectal cancer
Meyerhardt JA, Tepper JE, Niedzviecki D, Hollis DR, Schrag D, Ayanian JZ, O’Connell MJ, Weeks JC, Mayer RJ, Fuchs CS
Journal of Clinical Oncology 22 (1):166-174, 2004
Published Date 1/15/2004

Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup 0114
Tepper JE, O’Connell M, Hollis DR, Niedzviecki D, Cooke E, Mayer RJ
Published Date 10/1/2003

Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup 0114/CALGB 9081
Tepper J, O’Connell M, Hollis D, Niedzviecki D, Cooke E, Mayer RJ
Proc ASCO 21:507, 2002
Published Date 5/2/2002

Adjuvant therapy in rectal cancer: analysis of stage, sex and local control - final report of intergroup 0114/CALGB 9081
Tepper JE, O’Connell M, Niedzviecki D, Hollis DR, Benson AB, Cummings B, Gundersen LL, MacDonald JS, Martenson JA, Mayer RJ
Journal of Clinical Oncology 20(7):1744-1750, 2002
Published Date 4/1/2002
9081 Final report of adjuvant therapy in rectal cancer: analysis by treatment, stage, and gender (intergroup 0114)
Tepper J, O'Connell M, Niedzwiecki D, Hollis D, Mayer RJ, III AB, Cummings B, Gunderson LL, MacDonald JS, Martenson JA
Proc ASCO 20:489, 2001  Published Date 5/1/2001

9081 Impact of number of nodes retrieved on outcome in patients with rectal cancer
Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis DR, Mayer RJ, Benson AB, Cummings B, Gunderson L, MacDonald JS
Journal of Clinical Oncology 19:157-163, 2001  Published Date 1/1/2001

9081 Adjuvant postoperative fluorouracil modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114
Tepper JE, O'Connell MJ, Petroni GR, Hollis DR, Cooke EA, Benson AB, Cummings B, Gunderson L, MacDonald J, Martenson J

9081 Toxicity in the adjuvant therapy of rectal cancer: a preliminary report of Intergroup 0114 (CALGB 9081)
Proc ASCO 15:210, 1996  Published Date 1/1/1996

9082 A prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082
Journal of Clinical Oncology 23(10):2191-2200, 2005  Published Date 4/1/2005

9082 The impact of local/regional radiotherapy (RT), and its timing, on survival following lumpectomy/mastectomy and systemic chemotherapy in patients with ≥10 positive axillary nodes: Analysis of CALGB 9082
Int J Radiation Oncol, Biology, Physics 60(1):S136, 2004  Published Date 9/1/2004

9082 Updated results of a prospective randomized comparison of two doses of combination alkylating agents (AA) as a consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN)
Proc ASCO 20:81, 2001  Published Date 5/1/2001

9082 Preliminary analysis of radiotherapy data from CALGB 9082: variability of treatment fields for local/regional breast cancer and the impact of high-dose chemotherapy on the ability to deliver radiation therapy. Proceedings of the 41st annual ASTRO meeting.

9082 A Prospective, Randomized Comparison of Two Doses of Combination Alkylating Agents (AA) as Consolidation After CAF in High-Risk Primary Breast Cancer Involving Ten or More Axillary Lymph Nodes (LN): Preliminary Results of CALGB 9082/SWOG 9114/NCIC MA-13
Proc ASCO 18:1a–2, 1999  Published Date 5/15/1999

9091 Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: a preliminary report of intergroup study 113 (RTOG 89-11)
Proc ASCO 16:276a, 1997  Published Date 5/15/1997
Phase III trial of biochemical modulation of 5-Fluorouracil by IV or oral leucovorin or by interferon in advanced colorectal cancer: an ECOG/CALGB phase III trial


Proc ASCO 15:207, 1996

A Randomized Controlled Trial of Filgrastim During Re mission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111


Chemotherapy Compared With Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission

Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH


Comparison of autologous bone marrow transplant (AUTOBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): an ECOG intergroup study

Hurd DD, Cassileth PA, Harrington DP, Paietta E, Lazarus HM, Appelbaum FR, Bennett KJ, Wilman C, Magenis E, Wiernik PH

Proc ASCO 16:89a, 1997

Radiosensitization with Carboplatin for Patients With Unresectable Stage III Non Small Cell Lung Cancer: A Phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group

Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH

Journal of Clinical Oncology 17(1):4-11, 1999

Edatrexate (10-ethyl-deaza-aminopterin) (NSC 626715) with or without Leucovorin rescue for malignant mesothelioma: sequential Phase II trials of the Cancer and Leukemia Group B

Kindler HL, Belani CP, Herndon JN, Vogelzang NJ, Suzuki Y, Green MR


Edatrexate with oral leucovorin rescue for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B - CALGB 9131

Belani CP, Herndon J, Vogelzang NJ, Green MR

Proc ASCO 14: 352, 1995

A randomized Phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study


Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer. A Phase II trial of the Cancer and Leukemia Group B

Clamon GH, Herndon JE, Akerley WL, Green MR

Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer
Elias AD, Kumar P, Herndon JE, Skarin AT, Sugarbaker DJ, Green MR
Clinical Lung Cancer 4(2):95-103, 2002 Published Date 12/15/2002

A phase III comparison of “best local-regional therapy” with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): Preliminary results
Elias AD, Herndon JE, Kumar P, Sugarbaker DJ, Green MR
Proc ASCO 16:448a-1611, 1997 Published Date 5/15/1997

A phase III study of CAF+Leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B Study 9140
Journal of Clinical Oncology 21(9):1819-1824, 2003 Published Date 5/11/1997

Clinical outcomes of node-positive breast cancer patients treated with dose-intensified Adriamycin/ cyclophosphamide (AC) followed by Taxol (T) as adjuvant systemic chemotherapy (CALGB 9141)
Demetri GD, Berry DA, Norton L, Broadwater GJ, Robert N, Duggan DB, Henderson IC
Proc ASCO 16:143a, 1997 Published Date 5/1/1997

High-dose Cyclophosphamide plus Recombinant Human Granulocyte-Colony Stimulating Factor (rhG-CSF) in the treatment of follicular, low-grade Non-Hodgkin's Lymphoma: CALGB 9150
Lichtman SM, Niedzwiecki D, Schilsky RL, Johnson JL, Perri RT, Sklar J, Barcos MP, Peterson BA
Leukemia/Lymphoma 42:1255-1264, 2001 Published Date 8/1/2001

Feigal E, Petroni GR, Freter CE, Johnson JL, Barcos MP, Peterson BA
Proc ASCO 16:56a, 1997 Published Date 5/1/1997

Evaluation of Amifostine as a Chemoprotective Agent in Combination with Cyclophosphamide and Molgramostin (GM-CSF)
Budman DR, Rosner G, Lichtman S, Miller AA, Ratain MJ, Schilsky RL
Cancer Therapeutics 1(3):164-167, 1998 Published Date 7/1/1998

Modulation of Vinblastine Resistance in Metastatic Renal Cell Carcinoma with Cyclosorine A or Tamoxifen: A CALGB Study
Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL
Serum prostate specific antigen as a predictor of survival in patients treated with second-line hormonal therapy: CALGB 9181
Halabi S, Conaway MR, Small EJ, Vogelzang NJ, Dawson NA
The Prostate Journal 3:18-25, 2001  
Published Date 1/1/2001

A Randomized Study Comparing Standard versus Moderately High Dose Megestrol Acetate for Patients with Advanced Prostate Carcinoma: Cancer and Leukemia Group B Study 9181
Cancer 88(4):825-834, 2000  
Published Date 2/15/2000

Prostate Specific Antigen (PSA) as a Predictor of Survival: Cancer and Leukemia Group B (CALGB) 9181
Dawson NA, Halabi S, Hars V, Small EJ, Vogelzang NJ
Proc ASCO 18:314a–1209, 1999  
Published Date 5/15/1999

The Dynamics of Prostate Specific Antigen in Hormone Refractory Prostate Carcinoma: An Analysis of Cancer and Leukemia Group B Study 9181 of Megestrol Acetate
Vollmer RT, Dawson NA, Vogelzang NJ
Published Date 11/1/1998

Megastrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): prostate specific antigen (PSA) response and anti-androgen withdrawal (AAWD) data: Cancer and Leukemia Group B (CALGB) 9181
Proc ASCO 15: 241, 1996  
Published Date 1/1/1996

A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: a Cancer and Leukemia Group B study
Proc ASCO 14: 236, 1995  
Published Date 1/1/1995

Hydrocortisone With or Without Mitoxantrone in Men With Hormone Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Journal of Clinical Oncology 17 (8):2506, 1999  
Published Date 8/1/1999

Hydrocortisone (HC) with or without mitoxantrone (M) in patients (pts) with hormone refractory prostate cancer (HRPC): preliminary results from a prospective randomized Cancer and Leukemia Group B study (9182) comparing chemotherapy to best supportive care
Kantoff, Conaway M, Winer E, Picas J, Vogelzang NJ
Published Date 1/1/1996

Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the atra era: a report of 153 patients treated on intergroup 0129 and pethema LPA96 and LPA99
Blood 104(11):394, 2004  
Published Date 12/1/2004

All-trans-retinoic acid in acute promyelocytic leukemia: longterm outcome and prognosis factor analysis from the North American Intergroup protocol
Blood 100(13):4298-4302, 2002  
Published Date 12/15/2002

Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARa Isoform: Results from Intergroup Protocol 0129
Slack JL, Willman C, Anderssen JW, Li Y, Viswanatha D, Bloomfield CD, Tallman MS, Gallagher RE
Blood 95:398-403, 2000  
Published Date 10/15/2000

Predictive value of automated, quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia (APL): a SWOG, ECOG, CALGB intergroup study
Proc ASCO 19:5a, 2000  
Published Date 5/15/2000
Clinical description of 44 patients with Acute Promyelocytic Leukemia who developed Retinoic Acid syndrome
Blood 95(1):90-95, 2000

All-Trans Retinoic in Acute Promyelocytic Leukemia; long term outcome results and prognostic factor analysis from intergroup protocol 0129
Tallman MS, Anderson JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shephard L, Willman C, Bloomfield CD, Rowe JM, Wiernick PH
Blood 94:168a, 1999

All-Trans Retinoic Acid in Acute Promyelocytic Leukemia
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernick PH

Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia (APL): an intergroup molecular study

Secondary cytogenetic changes in acute promyelocytic leukemia: prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene. A Cancer and Leukemia Group B study

Effect of chemohormonal therapy in premenopausal node (+) receptor (+) breast cancer: an Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101)
Proc ASCO:15, 2003

Effect of chemohormonal therapy in premenopausal node (+) receptor (+) breast cancer: an Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101)
Proc ASCO 18:67a–249, 1999

Sixteen Week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an intergroup study
Journal of Clinical Oncology 16(7):2382-2391, 1998

CAF vs a 16 week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: an intergroup study
Proc ASCO 14: 96, 1995
9194 Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG 8814/CALGB 9194)
Proc ASCO 21:143, 2002 Published Date 5/1/2002

9194 Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to tamoxifen alone in postmenopausal, receptor (+), node (+) breast cancer: New findings from Phase III SWOG intergroup trial S8814 (INT 0100)
Proc ASCO 20:94, 2001 Published Date 5/2/2001

9195 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction: a phase III Intergroup study 0116/CALGB 9195/SWOG 9008
New England Journal of Medicine 345:725-730, 2001 Published Date 9/6/2001

9196 CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: a Phase III Intergroup Trial (SWOG-8897, INT-0102)
22nd Annual San Antonio Breast Cancer Symposium Dec 8-11, 1999 Published Date 12/8/1999

9196 CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102
Proc ASCO 16:2, 1997 Published Date 5/15/1997

9211 A phase II study of cladribine treatment for fludarabine refractory B-cell chronic lymphocytic leukemia: results from CALGB study 9211
Leukemia 17:323-327, 2003 Published Date 12/1/2003

9211 Cladribine has Clinical Activity in Patients with Fludarabine Refractory Chronic Lymphocytic Leukemia who Lack Pre-Treatment Cytopenias
Blood 98:2654, 2001 Published Date 11/1/2001

9221 Analysis of survival, AML transformation, and transfusion independence in patients with high-risk myelodysplastic syndrome receiving azacitidine determined using a prognostic model
Silverman LR, McKenzie DR, Peterson BL, Demakos EP, Holland JF, Larson RA
Blood 106(11):2523, 2005 Published Date 11/15/2005

9221 A new validated myelodysplastic syndrome prognostic model for use when cytogenetics are unavailable
Silverman LR, Germing U, McKenzie DR, Peterson BL, Larson RA
Blood 106(11):2527, 2005 Published Date 11/15/2005

9221 Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome patients > 65 years of age
Silverman LR, McKenzie DR, Peterson BL, Demakos EP, Malone N, Holland JF, Larson RA
Blood 106(112):2524, 2005 Published Date 11/15/2005

9221 Rates of infection and bleeding are not increased in patients with myelodysplastic syndromes treated with azacitidine compared with supportive care
Silverman LR, McKenzie DR, Peterson BL, Odchimar-Reissig R, Hinkle R, Backstrom JT, Larson RA
Blood 106(11):2525, 2005 Published Date 11/15/2005
Impact of Azacytidine on the quality of life of patients with Myelodysplastic Syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B Study
Published Date 5/15/2002

Randomized controlled trial of Azacitidine in patients with the myelodysplastic syndrome: a Study of the Cancer and Leukemia Group B (9221)
Published Date 5/15/2002

A Randomized Controlled Trial of Subcutaneous Azacitidine (AZA C) in Patients With the Myelodysplastic Syndrome (MDS): A Study of the Cancer and Leukemia Group B (CALGB)
Published Date 5/15/1998

The Impact of 5-Azacitidine on the Quality of Life of Patients With the Myelodysplastic Syndrome (MDS) Treated in a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB)
Proc ASCO 17:49a-189, 1998
Published Date 5/15/1998

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222
Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey F, Bloomfield CD, Larson RA, Schneider CJ
Blood 105(9):3420-3427, 2005
Published Date 5/1/2005

A comparison of sequential non-cross resistant therapy or ARA-C consolidation following complete remission in adult patients less than 60 years with acute myeloid leukemia: CALGB 9222
Moore JO, Powell BL, Velez-Garcia E, Kolitz JE, George SL, Dodge RK, Rizziere DA, Schiffer CA
Proc ASCO 16:14a, 1997
Published Date 5/1/1997

Free riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials
Bennett CL, Smith TJ, George SL, Hillner BE, Fleishman S, Niell HB
Published Date 1/1/1995

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
Annals of Oncology 10:597-600, 1999
Published Date 5/1/1999

A phase III trial evaluating the combination of cisplatin, etoposide, radiation therapy with or without tamoxifen in patients with limited stage small cell lung cancer
McCay EF, Bogart J, Herndon JE, Watson D, Evans L, Seagreen S, Green M
American Journal of Clinical Oncology 28(1):81-90, 2005
Published Date 2/28/2005

Interruptions of modest dose once-daily (QD) thoracic radiotherapy (TRT) do not correlate with outcome in limited small cell lung cancer (L-SCLC): analysis of CALGB 9235
Bogart JA, Watson DM, Mcclay EF et al
Proc American Radium Society, 2003
Published Date 6/23/2003
Dose intensive non-cross resistant alternating therapy for limited stage small cell lung cancer: A CALGB phase II trial
Westgate SJ, Lilenbaum RC, Herndon JE, Crawford J, Perry MC, Green MR
Proc ASCO 17:504a-1944, 1998

Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study
Levine E, Cirrincione CT, Szatrowski TP, Canellos GP, Norton L, Henderson IC
Am J Clin Oncol 22(3):218-222, 1999

Burkitt leukemia and lymphoma are curable with short course of intensive chemotherapy
Rizzieri DA, Johnson JL, Larson RA
The American Journal of Oncology Review 3(8):475-481, 2004

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B study 9251
Cancer 100(7):1438-1448, 2004

Brief duration high intensity chemotherapy for patients with small non-cleaved lymphoma or FAB L-3 acute lymphocytic leukemia: Results of CALGB 9251
Lee EJ, Petroni GR, Freter CE, Johnson JL, Barcos MP, Frizzera G, Bloomfield CD, Schiffer CA, Peterson BA

Efficacy and toxicity of brief duration, high intensity chemotherapy for small noncleaved cell lymphoma/L-3 ALL: results of CALGB 9251
Blood 96 (suppl 1):829a #3582, 2000

Brief duration high intensity chemotheraphy (CT) for for patients with small non-cleaved lymphoma and FAB L3 acute lymphocytic leukemia in adults: Preliminary results of CALGB 9251
Lee EJ, Petroni GR, Freter CE, Johnson JL, Schiffer CA, Peterson BA
Proc ASCO 16:24a, 1997

Anti-B4-Blocked-Ricin (NSC#639185) adjuvant therapy post-autologous bone marrow transplant: a phase III study
Proc ASCO 17:3a-8, 1998

Phase II study of infusional chemotherapy with doxorubicin, vincristine, and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive Non-Hodgkin's Lymphoma: CALGB 9255
Lichtman SM, Niedzwiecki D, Barcos MP, Carlisle TL, Cooper MR, Johnson JL, Peterson BA
Annals of Oncology 11:1141-1146, 2000

Phase II study of infusional chemotherapy with doxorubicin, vincristine, and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive Non-Hodgkin's lymphoma: CALGB 9255
Lichtman SM, Niedzwiecki D, Carlisle TL, Cooper MR, Johnson JL, Peterson BA
Proc ASCO 17:30a -117, 1998
Phase II Trial of Docetaxel in Non-Hodgkin’s Lymphomas: A study of the Cancer and Leukemia Group B
Budman DR, Petroni GR, Johnson JL, Cooper MR, Schlossman DM, Barcos MP, Peterson BA

CALGB 9256: a phase II trial of docetaxel in non-Hodgkin’s lymphoma patients
Budman DR, Petroni GR, Cooper MR, Johnson JL, Peterson BA
Proc ASCO 15:411, 1996

Phase I and Pharmacokinetic Trial of Paclitaxel in Patients with Hepatic Dysfunction: Cancer and Leukemia Group B 9264

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III Non-Small Cell Lung Cancer: A Cancer and Leukemia Group B Study
Graziano SL, Tatum A, Herndon JE, Box JW, Memoli V, Kern JA

Aspirin for the prevention of colorectal adenomas in patients with previous colorectal cancer: A randomized controlled trial: results of CALGB study 9270
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Schilsky RL

Quality of colonoscopy reporting: A process of care study
Robertson DJ, Lawrence LB, Shaheen NJ, Baron JA, Paskett E, Petrellie NJ, Sandler RS

Use of vitamins, minerals and nutritional supplements by participants in a chemoprevention trial
Sandler RS, Halabi S, Kaplan EB, Baron JA, Paskett ED, Petrellie NJ
Cancer 91:1040-1045, 2001

Combined-modality therapy of poor-prognosis anal carcinoma: a phase II study of CALGB
Proc Gastrointestinal Cancers Symposium:238, 2005

Combined-modality therapy of poor-risk anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B
Proc ASCO 18:237a–909, 1999

Phase III Double-Blind Randomized Trial of 13-Cis-Retinoic Acid (13-CRA) to Prevent Second Primary Tumors (SPT’s) in Stage I Non-Small Cell Lung Cancer
9294 A Phase III Study of Adjuvant Radiation Therapy (RT), 5-Fluorouracil (5-FU) and Levamisole (LEV) Vs 5-FU and LEV in Selected Patients With Resected, High-Risk Colon Cancer: Initial Results of Int 0130
Proc ASCO 18:235a–904, 1999 Published Date 5/15/1999

Cancer 97(6):1471-1480, 2003 Published Date 3/15/2003

Journal of Clinical Oncology 24(6):929-936, 2006 Published Date 2/20/2006

9312 Genetic polymorphisms associated with clinical outcome in the intergroup trial S9321, comparing high dose therapy with standard dose therapy for myeloma on behalf of ECOG, SWOG, CALGB, and the Bank on a Cure Santana-Davila R, Crowley J, Durie BG, Barlogie B, Greipp P, VanNess B
Blood 104(11):1495, 2004 Published Date 12/1/2004

9332 A phase II trial of vinorelbine (NVB) plus doxorubicin in relapsed small cell lung cancer
Johnson EA, Lake D, Herrndon JE, Box JW, Lynch TJ, Green MR
American Journal of Clinical Oncology 27(1):19-23, 2004 Published Date 2/14/2004

9332 Phase II trial of Navelbine (NVB) plus doxorubicin (DOX) in relapsed small cell lung cancer (SCLC)
Johnson EA, Lake D, Herrndon JE, Green MR
Proc ASCO 16:471a-1696, 1997 Published Date 5/15/1997

9332 Phase II Trial of Navelbine® (NVB) in Relapsed Small Cell Lung Cancer (SCLC)
Lake D, Johnson EA, Herrndon JE, Green MR
Proc ASCO 16:473a-1703, 1997 Published Date 5/15/1997

9334 A phase III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusion (CALGB 9334)
Chest 127(3):909-915, 2005 Published Date 3/3/2005

9334 Quality of life (QOL) advantage of sclerosis for malignant pleural effusion (MPE) via talc thoracoscopy over chest tube infusion of talc slurry: Cancer and Leukemia Group B study 9334
Proc ASCO 21:1418, 2002 Published Date 4/26/2002

9335 Video assisted wedge resection (VAR) and local radiotherapy for peripheral lung cancer in high risk patients: CALGB 9335 a phase II study
Shennib H, Bogart J, Herrndon JE, Kohman L, Keenan R, Green M, Sugarbaker D
Journal of Thoracic and Cardiovascular Surgery 129(4):813-818, 2005 Published Date 4/1/2005

9335 A prospective multi-center phase II trial of thorascopic wedge resection and radiotherapy for stage I high-risk patients: final report CALGB 9335
Shennib H, Bogart J, Herrndon JE, Kohman L, Green M, Keenan R, Sugarbaker D
Program American Association for Thoracic Surgery 82 Annual Mtg AATS, 2002 Published Date 4/2/2002

Proc ASCO 19:488a-1907, 2000 Published Date 5/15/2001
9342 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: results from CALGB 9342
Journal of Clinical Oncology 22(11):2061-2068, 2004 Published Date 6/1/2004

9342 The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342
Proc ASCO:9562, 2004 Published Date 5/1/2004

9342 Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer- Results From CALGB 9342
Winer EP, Berry DA, Duggan DB, Henderson IC, Cirrincione CT, Cooper MR, Norton L
Proc ASCO 17:101a-388, 1998 Published Date 5/15/1998

9343 A randomized comparison of lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) carcinoma of the breast: results of CALGB study 9343

9343 Comparison of lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) carcinoma of the breast
Proc ASCO 20:93, 2001 Published Date 5/1/2001

9343 Carcinoma of the breast in the geriatric population
Shank BM, Inouye P, Schnaper L, Bayske J, Shapiro CL, Berry DA, Wilder KL, Hughes KS
Surgical Rounds Jan:p16-20, 1997 Published Date 1/15/1997

9344 Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control for node positive breast cancer in CALGB 9344
Journal of Clinical Oncology 23(1):30-40, 2005 Published Date 1/1/2005

9344 Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control for node positive breast cancer in CALGB 9344
Proc ASCO abstract #38, 2003 Published Date 5/31/2003

9344 Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
Journal of Clinical Oncology 21(6):976-983, 2003 Published Date 3/15/2003

9344 Does addition of taxol after adjuvant adriamycin/cytotoxan chemotherapy affect local recurrence in patients treated with breast conserving therapy?
Sartor C, Henderson IC
Proc ASTRO, 2000 Published Date 5/15/2000

9344 Cost-effectiveness of the sequential addition of paclitaxel to doxorubicin plus cyclophosphamide in the adjuvant chemotherapy of patients with node positive breast cancer
Annemans L, Moermans K, Martin C, Norton L, Henderson IC
Proc ASCO 19:8 Onc Forum, 2000 Published Date 5/20/2000
Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC).


High dose CHOP induction therapy for poor prognosis aggressive NHL (CALGB 9351): FFP differs at high and low accrual institutions
Shipp MA, Niedzwiecki D, Johnson JL, Janicek M, Barcos MP, Gockerman JP, Peterson BA

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B Study
J Clin Oncol 13(9):2230-2237, 1995

Can social support reduce breast cancer patients’ psychological distress when faced with stressful life events?
Proc ASCO 18:589a–2276, 1999

An analysis of multiple staging management strategies for carcinoma of the esophagus:Computed tomography, endoscopic ultrasound, positron emission tomography and thoracoscropy/laparoscopy: CALGB 9380

A prospective trial of the feasibility of thoracoscropy/laparoscopy in staging for esophageal cancer: a phase II study
Krasna MJ, Reed CE, Niedzwiecki D, Hollis DR, Luketich JD, DeCamp M, Mayer RJ, Sugarbaker DJ

The feasibility of thoracoscropy/laparoscopy in the staging of esophageal cancer: Results of a prospective multicenter phase II trial (CALGB 9380)
Krasna MJ, Reed CE, Hollis DR, Niedzwiecki D, Luketich J, DeCamp MM, Mayer RJ, Sugarbaker DJ
Proc ASCO 19:924, 2000

A phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage I-IIA Hodgkin’s disease: SWOG 9133, CALGB 9391
Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI
Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A->C) in breast cancer patients with 0-3 positive nodes (Intergroup 0137/CALGB 9394/SWOG 9313)
Haskell CM, Green SJ, Sledge GW, Shapiro CL, Ingle JN, Lew D, Martin R, Livingston R, Osborne CK
Proc ASCO 21:36a (#142), 2002

A comparison of laparoscopically assisted colectomy and open colectomy for colon cancer

Short term quality-of-life outcomes following laparoscopic-assisted colectomy versus open colectomy for colon cancer: a randomized trial
Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G
JAMA 287(3):321-328, 2002

Early results of laparoscopic surgery for colorectal cancer

Measuring costs and clinical outcomes from prospective clinical trial and retrospective financial databases: experience gained from Cancer and Leukemia Group B study 9411.
Smith TJ, Herndon JE, Larson RA, Schiffer CA, McDonald K, Penberthy L, Weeks JC
Proc ASCO 16:420a, 1997

Post remission therapy with low-dose Interleukin-2 with or without intermediate pulse dose Interleukin-2 therapy is well tolerated in elderly patients with Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 9420
Clinical Cancer Research 8:2812-2819, 2002

Daily low dose interleukin 2 (IL-2) therapy with or without intermediate dose pulsing in acute myeloid leukemia (AML) patients ≥ 60 years old in first complete remission (CR1): feasibility study (CALGB 9420)
Blood 94 (supl 1):76a, 1999

Parallel phase I studies of Daunorubicin given with Cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B Study 9420
Lee EJ, George SL, Caligiuri MA, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith RG, Baer MR, Schiffer CA
Journal of Clinical Oncology 17 (9):2831-2839, 1999

A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and Leukemia Group B (CALGB) study 9420
Lee EJ, George SL, Caligiuri MA, Dodge RK, Smith RG, Szatrowski TP, Schiffer CA
Blood 90(10) Suppl:506a-2256, 1997
9430 Novel doublets in extensive small cell lung cancer: a randomized phase II study of topotecan/cisplatin, paclitaxel/cisplatin and paclitaxel/topotecan
Clinical Lung Cancer 3:205-210, 2002 Published Date 2/13/2002

9430 Paclitaxel (P) + cisplatin (C) + G-CSF (G) in patients with previously untreated extensive stage small cell lung cancer (E-SCLC): Preliminary analysis of CALGB 9430
Lyss AP, Herndon JE, Lynch TJ, Mauer AM, Green MR
Proc ASCO 18:468a–1806, 1999 Published Date 5/15/1999

9430 Toxicity of paclitaxel (P) and topotecan (T) in patients with previously untreated extensive small cell lung cancer (E-SCLC)
Proc ASCO 18:515a–1987, 1999 Published Date 5/15/1999

9431 Randomized phase II study of Cisplatin with Gemcitabine or Paclitaxel, or Vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for Stage IIIIB Non-Small Cell Lung Cancer
Vokes EE, Leopold KA, Herndon JE, Crawford J, Perry MC, Miller AA, Green MR
Journal of Clinical Oncology 20(20):4191-4198, 2002 Published Date 10/15/2002

9431 A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind C) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB 9431)
Vokes EE, Leopold KA, Herndon JE, Crawford J, Perry MC, Miller AA, Green MR
Proc ASCO 18:459a–1771, 1999 Published Date 5/15/1999

9431 Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer
Vokes EE, Leopold KA, Herndon JE, Green MR
Sem Oncol 24(3):S8-42–S8-45, 1997 Published Date 6/1/1997

9431 A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind C) and concomitant chemoradiotherapy (XRT) in Stage IIIIB non-small cell lung cancer (NSCLC): feasibility data (CALGB study 9431)
Vokes EE, Leopold KA, Herndon JE, Crawford J, Cooper MR, Clamon GH, Epstein J, Green MR
Proc ASCO 16:455a, 1997 Published Date 5/1/1997

9462 Phase I and pharmacological study of continuous infusion Topotecan in combination with Cisplatin in patients with advanced cancer: Cancer and Leukemia Group B study 9462
Journal of Clinical Oncology 16(10):3302-3309, 1998 Published Date 10/16/1998

9462 Pharmacologic study of continuous infusion topotecan and cisplatin in patients with advanced cancer: a Cancer and Leukemia Group B study (CALGB 9462)
Proc ASCO 16:200a, 1997 Published Date 5/1/1997

9462 Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462)
Proc ASCO 15: 485, 1996 Published Date 1/1/1996
Phase II study of fish oil capsules for patients with cancer cachexia; a Cancer and Leukemia Group B study

Barns CP, Halabi S, Clamon GH, Kaplan EB, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett ED

Cancer 101(2):370-378, 2004  Published Date 7/15/2004

Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia; a Cancer and Leukemia Group B study 9473


Clinical Cancer Research 5:3942-3947, 1999  Published Date 12/1/1999

The prognostic significance of plasma chromagranin A levels hormone-refractory prostate cancer patients treated on CALGB 9480

Taplin ME, George DJ, Halabi S, Sanford BL, Febbo PG, Hennessey KT, Mihos CG, Small EJ, Kantoff PW

Urology 66(2):386-391, 2005  Published Date 8/2/2005

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from CALGB 9480

George DJ, Halabi S, Shepard TF, Sanford BL, Vogelzang NJ, Small EJ, Kantoff PW

Clinical Cancer Research 11:1815-1820, 2005  Published Date 3/1/2005

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of intergroup 0159/CALGB 9480


Cancer 101(10):2202-2208, 2004  Published Date 11/15/2004

Prognostic significance of plasma chromagranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480

Taplin ME, George DJ, Halabi S, Sellers WR, Sanford BL, Hennessy KT, Mihos CG, Small EJ, Kantoff PW

Proc ASCO:4557, 2004  Published Date 5/1/2004

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of CALGB 9480/Intergroup 0159


Journal of Clinical Oncology 20 (16):3369-3375, 2002  Published Date 8/15/2002

Prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) in men with hormone refractory prostate cancer (HRPC)

Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ

Journal of Clinical Oncology 19(12):3025-3028, 2001  Published Date 7/15/2001

Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone-refractory prostate cancer: CALGB 9480

George DJ, Halabi S, Shepard TF, Hayes DF, Vogelzang NJ, Small EJ, Kantoff PW

Clinical Cancer Research 7(7):1932-1936, 2001  Published Date 7/15/2001

VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study


Cancer Research 61:2533-2536, 2001  Published Date 3/15/2001

RT-PCR for prostate specific antigen (PSA) in peripheral blood (PB) predicts survival duration in patients with hormone refractory prostate cancer (HRPC)—A CALGB study

Kantoff PW, Halabi S, Farmer D, Hayes DF, Vogelzang NJ, Small EJ

Proc ASCO 19:336a-1323, 2000  Published Date 5/20/2000

VEGF and basic FGF urine levels as predictors of response to therapy with Suramin in CALGB 9480, a Phase III study of Hormone Refractory Prostate Cancer (HRPC) patients


Proc ASCO 19:347a-1367, 2000  Published Date 5/20/2000

Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer (HRPC).


Proc ASCO 19:328a-1291, 2000  Published Date 5/20/2000
A phase III trial of 3 different doses of suramin (SUR) in metastatic hormone refractory prostate cancer (HRPC): Safety profile of CALGB 9480

Proc ASCO 17:347a-1339, 1998
Published Date 5/15/1998

Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, cost effectiveness and molecular markers

Journal of Clinical Oncology 24(9):1395-1403,
Published Date 3/20/2006

Final analysis of hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB randomized trial of efficacy, quality of life, cost effectiveness and molecular markers

Proc Gastrointestinal Cancers Symposium:183, 2005
Published Date 1/27/2005

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity

Published Date 6/1/2003

Hepatic Arterial Infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer; a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers

Proc ASCO abstract #1010, 2003
Published Date 5/31/2003

Thymidylate Synthase gene polymorphism determines thymidylate synthase mRNA levels and outcome of metastatic colorectal carcinoma treated with 5-Fluorouracil

Published Date 5/1/2001

Breast cancer genetic studies in cooperative clinical cancer trials

McIntyre OR, Millikan RC, Dressler LG, Kornblith AB, Broadwater GJ, Sandler DP, Barcos MP, Collyar D
DOD Breast Cancer Research Program, 1999
Published Date 10/31/1999

Genetic testing in breast cancer cooperative clinical trials: Barriers and opportunities

Millikan RC, Kornblith AB, McIntyre OR, Berry DA, Broadwater GJ, Sandler DP, Karas KS, Dressler LG, Gross LS, Collyar D, Schilsky RL
Cancer Therapeutics 1(2):96-100, 1998
Published Date 6/3/1998

Induction chemoradiation and surgical resection for non-small cell lung carcinomas involving the superior sulcus: initial results of SWOG 9416 (Intergroup 0160/CALGB 9495)

Journal of Thoracic and Cardiovascular Surgery 121(3):472-483, 2004
Published Date 9/1/2004

Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of SWOG 9416/CALGB 9495/Intergroup 0160

Published Date 3/1/2001
9497 Health status and quality of life in patients with early-stage Hodgkin’s disease: a companion study to CALGB 9391/SWOG 9133
Journal of Clinical Oncology 21(18):3512-3519, 2003 Published Date 9/15/2003

9498 A phase III intergroup (INT-0153) randomized trial of 5-FU/leucovorin/levamisole versus 5-FU continuous infusion levamisole for adjuvant treatment of stage III and high risk stage II colon cancer
Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Riskin SE, MacDonald JS
Journal of Clinical Oncology 23:1819-1825, 2005 Published Date 3/20/2005

9511 Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: CALGB 9511
Wetzler M, Sanford BL, Oscar K, Kertzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA
Blood 106(11):1825, 2005 Published Date 11/15/2005

9511 High levels of Wilms’s tumor gene (WT1) expression is detected in the majority of newly diagnosed acute lymphoblastic leukemia of adults: implications for prognosis and monitoring of minimal residual disease: CALGB 9511
Stock W, Sher D, Dodge RK, Marciano E, Caligiuri M, Frankel S, Larson RA, Bloomfield CD
Blood 92(suppl 1):223a (#915), 1998

9511 Toxicity and pharmacokinetics of Peg-Asparaginase (PEG-asn) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511
Frankel SR, Kertzberg J, DeOleiveira D, Dodge RK, Peterson BL, Powell BL, Kolitz JE, Larson RA, Schiffer CA
Blood 90(Suppl 1):334a-1491, 1997 Published Date 11/15/1997

9511 Toxicity and pharmacokinetics of peg-asparaginase (peg-asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511
Frankel SF, Kertzberg J, DeOleiveira D, Dodge R, Peterson B, Powell BL, Larson RA, Schiffer CA
Blood 88 (10): 669a, 1996 Published Date 1/1/1996

9530 Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
Lung Cancer 31(2-3):311-317, 2001 Published Date 1/5/2001

9530 Gemcitabine for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9530)
Millard F, Herndon JE, Vogelzang NJ, Green MR
Proc ASCO 16:475a, 1997 Published Date 5/1/1997

9532 Paclitaxel/Ifosfamide or Navelbine/Ifosfamide Chemotherapy for Advanced Non-Small Cell Lung Cancer: CALGB 9532
Perry MC, Ihde DC, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR
Lung Cancer 28:63-68, 2000 Published Date 6/1/1996

9532 Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer; CALGB 9532
Perry MC, Ihde D, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR
Lung Cancer 28(1):63-68, 2000 Published Date 4/1/2000

9532 Paclitaxel/ifosfamide chemotherapy for advanced non-small cell lung cancer; CALGB 9532
Perry MC, Ihde DC, Herndon JE, Box JW, Ijames ET, Green MR
Proc ASCO 17:470a-1809, 1998 Published Date 5/15/1998

9532 Paclitaxel/ifosfamide chemotherapy for advanced non-small cell lung cancer (NSCLC): CALGB 9532
Perry MC, Ihde DC, Herndon J, Atkins JN, Pillemer EA, Chahinian AP, R.Green M
Proc ASCO 16:478a-1721, 1997 Published Date 5/15/1997

9532 Vinorelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer (NSCLC): CALGB 9532
Ihde DC, Perry MC, Herndon JE, Atkins JN, Pillemer EA, Chahinian AP, Green MR
Proc ASCO 16:471a-1693, 1997 Published Date 5/1/1997
9534 Induction paclitaxel/carboplatin followed by concurrent chemoradiation for unresectable stage III non-small cell lung cancer: a limited-access study - CALGB 9534

9534 Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial by the Cancer and Leukemia Group B.

9565 Pharmacokinetically-guided gemcitabine (dFdC) infusion scheduling to reduce potentially excessive plasma dFdC concentrations

9565 Evaluation of potentially excessive plasma gemcitabine (dFdC) concentrations produced by 30-minute dFdC infusions

9565 A phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: CALGB 9565

9565 Phase I study of gemcitabine (G) in patients with organ dysfunction: CALGB 9565

9581 Phase III study of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)

9583 Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: results from CALGB 9583

9583 A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: results of CALGB 9583

9583 Prognostic significance of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for Prostate Specific Antigen (PSA) in metastatic prostate cancer: A nested study within CALGB 9583
Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW Journal of Clinical Oncology 21(3):490-495, 2003 Published Date 6/1/2003

9583 Prospective assessment of adrenal androgen levels as predictors of survival in androgen independent prostate cancer patients treated with ketoconazole

9583 Reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) as a prognostic factor for survival among androgen independent prostate cancer patients (AiCaP)
A prospective randomized study of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients
Small EJ, Halabi S, Picus J, Cen YF, Vogelzang NJ
Proc ASCO 20:695, 2001

Combined Etoposide, Ifosfamide, and Cisplatin in the Treatment of Patients with Advanced Thymoma and Thymic Carcinoma
Cancer 91:2010-2015, 2001

Phase III trial of concurrent chemotherapy and radiotherapy vs CT/RT followed by surgical resection for stage IIIa(pN2) non-small cell lung cancer: outcomes and implications for surgical management in North American Intergroup 0139
Lung Cancer 49(suppl 2):S15, P-035, 2005

Phase III study of PSC-833 in combination with vincristine, doxorubicin, and dexamethasone (PSC-833/VAD) versus VAD alone in patients with relapsing or refractory multiple myeloma (E1A95)

Autologous stem cell transplantation for acute myeloid leukemia in second remission
Linker C, George S, Hard D, Larson RA
Blood 98:689a (2881), 2001

Overexpression of the ETS transcription factor ERG predicts a worse outcome in acute myeloid leukemia with normal karyotype: CALGB study 9621
Journal of Clinical Oncology 23(36):9234-9242, 2005

Independent validation of prognostic relevance of a previously reported gene-expression signature in acute myeloid leukemia with normal cytogenetics: a CALGB study
Blood 106(11):755, 2005

Overexpression of the ERG gene is an adverse prognostic factor in acute myeloid leukemia with normal cytogenetics: a CALGB study
Blood 106(11):335, 2005

Dose escalation studies of Cytarabine, Daunorubicin, and Etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with Acute Myeloid Leukemia <60 years old: Final induction results of CALGB Study 9621
Journal of Clinical Oncology 22(21):4290-4301, 2004

Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): results from CALGB 9621
Blood 102 (11):#612, 2003
A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) < 60 years old with normal or unfavorable cytogenetics: results from CALGB 9621
Blood 102 (11):#609, 2003
Published Date 11/16/2003

Consolidation therapy by cytogenetic risk in adults with AML < 60 years in first complete remission
Blood 98:2879, 2001
Published Date 11/1/2001

Dose escalation studies of Ara-C(A), Daunorubicin (D), and Etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) <60 years: final induction results
Blood 98:1928, 2001
Published Date 11/1/2001

Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3
Cancer Research 61:7233-7239, 2001
Published Date 10/1/2001

Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A Cancer and Leukemia Group B Study
Published Date 7/4/2001

Morphology and CBFß/MYH11 in AML (CALGB Study 9621)
Lab Invest 80:165a #967, 2000
Published Date 11/11/2000

Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with AML < 60 years, preliminary results of CALGB 9621
Blood 93 (suppl 1):384a #1705, 1999
Published Date 4/1/1999

Cytopathic risk-adapted consolidation followed by immunotherapy with recombinant interleukin-2 (rIL-2) in patients < 60 years with AML in first complete remission (CR) preliminary results of CALGB 9621
Blood 93 (suppl 1):579a #2582, 1999
Published Date 4/1/1999

A comparison of cytogenetic and molecular genetic detection of t(8;21)(q22;q22) and inv (16)(p13q22) in adults with de novo acute myeloid leukemia (AML): A Cancer and Leukemia Group B study
Blood 92 (suppl 1):77a (#313), 1998
Published Date 11/15/1998

High dose Doxorubicin, Dexrazoxane and GM-CSF in malignant mesothelioma: A phase II study CALGB 9631
Kosty MP, Herndon JE, Vogelzang NJ, Kindler HL, Green MR
Published Date 4/25/2001
9665 Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9663
*Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, Sugarbaker DJ, Schlisky RL, Green MR*
*Proc ASCO:7019, 2004*

9661 A phase I trial of escalating doses of trastuzumab combined with daily Subcutaneous Interleukin-2: report of Cancer and Leukemia Group B 9661
*Clinical Cancer Research 8:3718-3727, 2002*

9661 Phase I trial of recombinant human anti-Her2 monoclonal antibody (H) plus low-dose Interleukin-2 (IL-2) in solid tumors
*Proc ASCO 18:184a–710, 1999*

9663 Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration resistant prostate cancer - A CALGB study
*Ross RW, Halabi S, Ou S, Rajeshkumar B, Woda B, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW*
*Clinical Cancer Research 11(22):8109-8113, 2005*

9663 Androgen receptor mutations in androgen independent prostate cancer
*Journal of Clinical Oncology 21(14):2673-2678, 2003*

9663 Androgen receptor mutations in androgen independent prostate cancer (AIPCA) do not correlate with anti-androgen withdrawal response
*Taplin ME, Halabi S, Rajeshkumar B, McQuain C, Woda BA, Picus J, Hayes DF, Vogelzang NJ, Small EJ*
*Proc ASCO 20:1738, 2001*

9663 Androgen receptor analyses in androgen independent prostate cancer (AIPCA): Cancer and Leukemia Group B (CALGB) 9663.
*Taplin M, Rajeshkumar B, Woda B, Halabi S, Prins GS, Picus J, Hayes DF, Vogelzang NJ, Small EJ*
*Proc ASCO 19:330a-1297, 2000*

9665 Promoter methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia
*Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C*
*Cancer Research 66(2):653-658, 2006*

9665 Acute myeloid leukemia with deletion 9q is associated with CEBPA loss-of-function mutations
*Frohling S, Schlenk RF, Krauter J, Thiede C, Haase D, Harder L, Kreitmeier S, Bloomfield CD, Caligiuri MA, Dohner H, Dohner K*
*Genes Chromosomes Cancer 42(4):427-432, 2005*

9665 Global assessment of promoter methylation in a murine model of cancer identifies ID4 as a putative novel tumor suppressor gene in human leukemia
*Nature Genetics 37(3):265-274, 2005*

9665 Global assessment of promoter methylation in a murine model of cancer identifies ID4 as a putative novel tumor suppressor gene in human leukemia
*Blood 104(11):3488, 2004*

9665 Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia
*Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Look AT*
*Blood 103(5):1919-1911, 2004*
BCR/ABL activates mdm2 mRNA translation via the La antigen
Cancer Cell 3(2):145-60, 2003 Published Date 2/1/2003

High affinity interleukin-3 receptor expression on blasts from patients with AML correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE
Leukemia Research 25(10):875-881, 2001 Published Date 10/25/2001

Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci
Blood 97(10):3226-33, 2001 Published Date 5/15/2001

Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics
Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, Chapelle Ad, Krahe R
Nature Genetics 27:65, 2001 Published Date 4/1/2001

Gene expression profiling reveals fundamental biological differences in AML with isolated trisomy 8 and normal cytogenetics
Virtaneva KI, Wright FA, Tanner SM, Yuan Bo, Lemon WJ, Caligiuri MA, Bloomfield CD, Chappelle Ad, Krahe R
Proc Natl Acad Sci USA 98(3):1124-1129, 2001 Published Date 1/30/2001

High affinity interleukin-3 receptor expression on blasts from patients with AML correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
Alexander RL, Ramage J, Klein B, Kucera GL, Caligiuri MA, Bloomfield CD, Frankel AE
Blood 96:304a, 2000 Published Date 5/15/2000

DNA hypermethylation in AML: nonrandom patterns with preferential involvement of chromosome 11
Rush LJ, Gao X, Wright FA, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C
Blood 96:501a, 2000 Published Date 5/15/2000

Aberrant CpG-island methylation has non-random and tumour-type-specific patterns

Aberrant DNA Methylation in AML
Rush L, Yu L, Bloomfield CD, Caligiuri MA, Plass C
Vet Pathol 36(5):488, 1999 Published Date 11/16/1999

Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene.
Oncogene 18(20):3159-3165, 1999 Published Date 11/11/1999

Gene expression in AML with trisomy 8
Tanner SM, Virtaneva K, Rush L, Caligiuri MA, Bloomfield CD, Plass C, Krahe R, Chapelle Ad
European J of Human Genetics 7 (suppl 1):92 (P-300), 1999 Published Date 11/11/1999

Novel genes in AML with trisomy 8
Tanner SM, Virtaneva K, Rush L, Caligiuri MA, Bloomfield CD, Plass C, Krahe R, Chappelle Ad
American Journal of Human Genetics 65 (4) Suppl A325:1834, 1999 Published Date 11/11/1999

Gene expression pattern recognition for cancer classification
Blood 94:656a, 1999 Published Date 11/11/1999

Partial tandem duplication of MLL (MLL PTD): quantitative assessment of transcript copy number in AML with and without evidence of MLL gene rearrangement
Whitman SP, Strout MP, Maghraby EA, Marcucci G, Bloomfield CD, Caligiuri MA
Blood 94:53a, 1999 Published Date 11/11/1999
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
Science 286:531-537, 1999

Barriers to clinical trial participation of older women with breast cancer
Kemeny MM, Muss HB, Kornblith AB, Peterson B, Wheeler J, Cohen HJ

Survey of oncologist’s perceptions of barriers to accrual of older breast cancer patients to clinical trials
Cancer 95(5):989-996, 2002

Barriers to participation of older women with breast cancer in clinical trials
Kemeny MM, Muss HB, Kornblith AB, Peterson B, Wheeler JD, Cohen HJ
Proc ASCO 19:602a-2371, 2000

Long-term adjustment of survivors of early stage breast cancer treated by adjuvant chemotherapy twenty years ago: companion to CALGB 7581
Proc ASCO 20:1622, 2001

Higher Doses of Mitoxantrone among men with Hormone Refractory Prostate Cancer: a Cancer and Leukemia Group B study
Levine E, Halabi S, Kaplan EB, Roberts JD, Rago R, Atkins JN, Vogelzang NJ
Cancer 94(3):665-672, 2002

Preliminary results of CALGB 9680: A phase II trial of high dose mitoxantrone/GM-CSF and low dose steroids in hormone refractory prostate cancer (HRPC)
Levine E, Halabi S, Hars V, Rago R, Vogelzang NJ
Proc ASCO 17:336a-1297, 1998

Phase II study of oral Eniluracil, 5-Fluorouracil, and Leucovorin in patients with advanced colorectal cancer
Meropol NJ, Niedzwiecki D, Hollis DR, Schilsy RL, Mayer RJ
Cancer 91(7):1256-1263, 2001

Management of recurrent prostate cancer after radiotherapy: preliminary results of CALGB 9687, a contemporary salvage prostatectomy series
Sokoloff MH, Halabi S, Sanford BL, Eastham JA, Mohler JL, Walther PJ, Steinberg GD, Vogelzang NJ, Small EJ
ASCO Prostate Symposium:166, 2005

Select high-risk genetic factors predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: preliminary justification for risk adapted therapy (CALGB 9712)

Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: results from CALGB 9712
Blood 104(11):476, 2004

Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) study 9712
Morrison VA, Byrd JC, Peterson BL, Rai KR, Larson RA
Blood 102 (11):#1606, 2003
Randomized phase II study of concurrent versus sequential treatment of rituximab with fludarabine in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: superior complete response rates with concurrent therapy: results of CALGB 9712


Concurrent Rituximab and Fludarabine has a Higher Complete Response Rate than Sequential Treatment in Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Blood 98(11):#3212, 2001

Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia

Proc ASCO 20:1116, 2001

Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with AML: Cancer and Leukemia Group B study 9720

Blood 100:1224-1232, 2002

Phase III study of PSC-833 modulation of multidrug resistance in previously untreated acute myeloid leukemia patients > 60 years (CALGB 9720)

Baer MR, George SL, Dodge RK, Cooke KD, Caligiuri MA, Powell BL, Kolitz JE, Larson RA
Blood 94:383a, 1999

Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a randomized trial of efficacy, quality of life, and cost effectiveness

Journal of Clinical Oncology 23(1):190-196, 2005

Single agent versus combination chemotherapy in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness: CALGB 9730

Proc ASCO 21:2, 2002

Single agent versus combination chemotherapy in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness

Proceedings at ECCO, 2001

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B


CALGB 9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC)

Proc ASCO 18:462a–1783, 1999
A randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer: CALGB 9732
Journal of Clinical Oncology 23:3752-3759, 2005
Published Date 6/1/2005

Randomized phase III intergroup trial of etoposide (VP-16) and cisplatin (DDP) +/- paclitaxel (Tax) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC): CALGB 9732
Niell HB, Herndon JE, Miller AA, Green MR
Proc ASCO 21:1169, 2002
Published Date 5/2/2002

Irinotecan for malignant mesothelioma: a phase II study
Kindler HL, Herndon JE, Zhang K, Green MR
Lung Cancer 48(3):423-428, 2005
Published Date 2/16/2005

CPT-11 in Malignant Mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 9733).
Kindler HL, Herndon JE, Vogelzang NJ, Green MR
Proc ASCO 19:505a-1978, 2000
Published Date 5/20/2000

Updated analysis of a phase III study of surgical resection and chemotherapy (paclitaxel/arboplatin) with or without radiation therapy for resected stage III non-small cell lung cancer
Perry MC, Kohman LJ, Bonner J, Gu L, Wang X, Vokes EE, Green MR
Proc ASCO 7145:2005, 2005
Published Date 5/15/2005

A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) with or without radiation therapy for resected stage III non-small cell lung cancer
Lung Cancer 41(S2):S55, 2003
Published Date 8/1/2003

Dose-dense (DD) AC followed by paclitaxel is associated with mild, frequent anemia compared to sequential (S) and/or less DD treatment: update by CALGB on Breast Cancer Intergroup trial C9741 with ECOG, SWOG, and NCCTG
Proc ASCO:620, 2005
Published Date 5/16/2005

A randomized trial of dose dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: preliminary report of intergroup CALGB 9741
Published Date 4/15/2003

Superiority of dose dense over conventionally scheduling and equivalence of sequential vs. combination adjuvant chemotherapy for node-positive breast cancer: CALGB 9741/Intergroup 9741
San Antonio Breast Cancer Symposium:15, 2002
Published Date 12/10/2002

ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760)
Proc ASCO:6551, 2005
Published Date 5/16/2005
Poor correspondence between clinical and pathologic staging in stage I non-small cell lung cancer: results from CALGB 9761, a prospective trial

Lung Cancer 48(2):241-246, 2005

Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B (CALGB) 9761


Poor correlation between clinical and pathological staging in stage I non-small cell lung cancer: results from CALGB 9761

Proc ASCO abstract #2550, 2003

Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B (CALGB) Trial 9761

Proc ASCO abstract #2552, 2003

Molecular staging of lung cancer: Real-time polymerase chain reaction estimation of lymph-node micrometastatic tumor cell burden in Stage I Non-Small Cell Lung Cancer: Preliminary Results of Cancer and Leukemia Group B Trial 9761


Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology

Journal of Clinical Oncology 24(12), 2006

Clinical pharmacology of paclitaxel in relation to patient age

Proc ASCO 20:265, 2001

Clinical Pharmacology of Paclitaxel in Relation to Patient Age: CALGB 9762

Proc ASCO 18:190a–732, 1999

Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors

Clinical Cancer Research 10:8325-8331, 2004

Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors

Proc ASCO abstract #500, 2003
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy


_Blood_ 106(1):345-352, 2005  
Published Date 7/1/2005

Activation of the silenced MLL (ALL-1) wild-type allele in acute myeloid leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death


_Blood_ 102(11):#775, 2003  
Published Date 11/16/2003

A Phase II Study of Docetaxel, estramustine, and low dose hydrocortisone on the quality of life in men with hormone refractory prostate cancer and their partners: CALGB 9780

*Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese DM, Holland JC, Vogelzang NJ*

Published Date 5/15/2001

A phase II study of Docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: CALGB 9780

*Savarese DM, Halabi S, Hars V, Akerley WL, Godley PA, Hussain A, Taplin ME, Small EJ, Vogelzang NJ*

Published Date 5/1/2001

The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer [HRPC] and their partners.

*Kornblith AB, Herndon JE, Zuckerman EL, Godley PA, Savarese DM, Vogelzang NJ, Holland JC*

_Proc ASCO_ 19:620a-2441, 2000  
Published Date 5/20/2000

A phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: preliminary results of CALGB 9780

*Savarese DM, Taplin M, Halabi S, Hars V, Kreis W, Vogelzang NJ*

_Seminars in Oncology_ 26:39, 1999  
Published Date 11/11/1999

A Phase II Study of Docetaxel, Estramustine, and Low Dose Hydrocortisone in Hormone Refractory Prostate Cancer: CALGB 9780

*Savarese DM, Taplin M, Marchesani BJ, Kreis W, Akerley WL, Godley PA, Halabi S, Vogelzang NJ*

_Proc ASCO_ 18:321a–1234, 1999  
Published Date 5/15/1999

A phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: preliminary results of CALGB 9780

*Savarese DM, Taplin M, Marchesani BJ, Kreis W, Akerley WL, Godley PA, Halabi S, Vogelzang NJ*

Published Date 4/1/1999

Efficacy of peripheral androgen blockade on prostate cancer: results of CALGB 9782

*Picus J, Halabi S, Small EJ, Hussain A, Philips GK, Kaplan EB, Vogelzang NJ*

_Proc ASCO_ :4559, 2004  
Published Date 5/1/2004

Efficacy of peripheral androgen blockade on prostate cancer: initial results of CALGB 9782

*Picus J, Halabi S, Dawson NA, Small EJ*

_Proc ASCO_ 21:727, 2002  
Published Date 5/2/2002
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup trial (S9628)

Dhodapkar MV, Rasmussen E, Hussein M, Larson RA, Solomon A, Crowley J, Barlogie B

Blood 104(12):3520-3526, 2004

Dose intensity of CHOP alone or with rituximab in diffuse large B-cell lymphoma in patients >60 years of age: an analysis of the intergroup trial (CALGB 9793/ECOG/SWOG 4494)


Annals of Oncology 16(s5):v102 #224, 2005

Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF-T with tamoxifen alone


Proc ASCO 17:97a-374, 1998

CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC

Seidman AD, Berry DA, Cirrincione CT, Harris LN, Dressler LG, Mass HB, Naughton M, Norton L, Winer EP, Hudis CA

Proc ASCO:512, 2004

High level of Wilms Tumor gene (WT1) expression is detected in the majority of newly diagnosed acute lymphoblastic leukemia (ALL) of adults: implications for prognosis and monitoring of minimal residual disease (MRD)

Stock W, Sher D, Dodge RK, Murciano E, Caligiuri MA, Frankel SR, Larson RA, Bloomfield CD

Blood 92(10) Suppl:#915, 1998

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863


Annals of Oncology 14:1783-1790, 2003

Phase I study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy


Proc ASCO 20:293, 2001
APC Promoter Hypermethylation Contributes to the Loss of APC Expression in Colorectal Cancers with Allelic Loss on 5q1

Arnold CN, Goel A, Niedzviecki D, Dowell JM, Wasserman L, Compton CC, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Biology and Therapy 3(10):960-964, 2004  Published Date 10/1/2004

Frequent inactivation of PTEN by promoter hypermethylation and its association with microsatellite instability-high (MSI-H) in sporadic colorectal cancers

Goel A, Arnold CN, Niedzviecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Research 64(9):3014-3021, 2004  Published Date 4/1/2004

Epigenetic inactivation of RUNX3 is an important event in TGF-b mediated signaling in high-frequency microsatellite unstable (MSI-H) sporadic colon cancers

International Journal of Cancer 112:754-759, 2004  Published Date 4/1/2004

Evaluation of microsatellite instability, HMLH1 expression and HMLH1 promoter hypermethylation in defining the phenotype of colorectal cancer: a study from CALGB 9865

Arnold CN, Goel A, Compton CC, Marcus V, Niedzviecki D, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR
Cancer Biology and Therapy 3(1):73-78, 2004  Published Date 1/5/2004

Characterization of sporadic colon cancer by patterns of genomic instability: results from CALGB 9865

Cancer Research 63(7):1608-1614, 2003  Published Date 4/1/2003

RUNX3: a novel tumor suppressor gene frequently silenced by promoter hypermethylation in sporadic colon cancers: results from CALGB 9865

Proc DDW online abstract ID:102989, 2003  Published Date 4/1/2003

Evaluation of Microsatellite Instability, hMLH1 Expression and hMLH1 Promoter Hypermethylation in Defining the Phenotype of Colorectal Cancer: a Study from CALGB 9865

Arnold CN, Goel A, Compton CC, Marcus V, Niedzviecki D, Wasserman L, Mayer RJ, Bertagnolli MM, Boland CR
Proc DDW online abstract ID:100611, 2003  Published Date 4/1/2003

Frequent inactivation of PTEN by Promoter Methylation in the Microsatellite-High (MSI-H) sporadic colorectal cancers

Gastroenterology 122(5A):S899, 2002  Published Date 6/1/2002

Tumor suppressor genes are a ‘target’ of Promoter Hypermethylation in MSI-H sporadic colorectal cancers: New insights into the mechanism of colon carcinogenesis

Gastroenterology 122(5A):133, 2002  Published Date 6/1/2002

Promoter Hypermethylation plays a principal role in colon carcinogenesis in chromosomally and microsatellite stable tumors

Gastroenterology 122(5A):M906, 2002  Published Date 6/1/2002

APC Promoter Hypermethylation contributes strongly to loss of APC expression in colorectal cancers with allelic loss on 5q

Arnold CN, Goel A, Compton C, Niedzviecki D, Mayer RJ, Bertagnolli MM, Boland CR
Gastroenterology 122(5A):S886, 2002  Published Date 6/1/2002

Microsatellite-High (MSI-H) tumors are not associated with LOH at the APC locus compared to microsatellite-Low/Stable (MSI-L/MSS) tumors

Gastroenterology 120(5A):296, 2001  Published Date 1/5/2001

Chromosomal vs microsatellite instability in colorectal cancers: Evidence for previously unrecognized pathways

Goel A, Arnold CN, Chang DK, Ricciardiello L, Chauhan DP, Carethers JM, Wasserman L, Bertagnolli MM, Boland CR
Gastroenterology 120(5A):163, 2001  Published Date 1/5/2001

Somatic frameshift mutations in MBD4 (MED1) are not exclusively associated with microsatellite high (MSI-H) colorectal tumors

Gastroenterology 120(5A):293, 2001  Published Date 4/1/2001
A panel of mono and di nucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer
Gastroenterology 120(5A):599, 2001
Published Date 4/1/2001

The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in caucasian and African American patients with solid tumors:CALGB 9871
Proc ASCO:2043, 2004
Published Date 5/1/2004

Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women on adjuvant tamoxifen
Garber JE, Halabi S, Kaplan EB, Edge S, Dressler LG, Paskett ED, Berliner N
Proc ASCO:508, 2005
Published Date 5/16/2005

Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia: a phase I/II study from CALGB
Blood 106(11):145, 2005
Published Date 11/15/2005

Fludarabine and cyclophosphamide produce a higher complete response rate and more durable remissions than fludarabine in pateients with previously untreated CLL: intergroup trial E2997
Flinn IW, Kumm E, Grever MR, Neuberg D, Dewald GW, Bennett JM, Palette EM, Hussein MA, Moore DF, Tallman M
Blood 104(11):475, 2004
Published Date 12/1/2004

Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia is adversely impacted by high risk genetic features: results from intergroup E2997
Blood 104(11):3487, 2004
Published Date 12/1/2004

Differences in prognostic factors and outcomes in African-Americans and Caucasians with Acute Myeloid Leukemia
Blood 103(11):4036-4042, 2004
Published Date 6/1/2004

Racial differences in prognostic factors and outcome in acute myeloid leukemia, CALGB 10104
Sekeres MA, Dodge RK, Bloomfield CD, Larson RA, Stone RM
Blood 100 (suppl 1):323, 2002
Published Date 12/20/2002

Feasibility of administering oblimersen (G3139: Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia: CALGB 10107
Wetzler M, Yu D, Odenike OM, Feldman EJ, Hurd DD, Hoke EE, Hars V, Larson RA
Blood 106(11):1097, 2005
Published Date 11/15/2005
Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB study 10301

Orlowski RZ, Peterson BL, Caligiuri MA, Kelly M, Larson RA

Haematologica 90(s1):PO.730, 2005

Published Date 4/1/2005

Phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL)

DeAngelo DJ, Yu D, Dodge RK, Coutre SE, Mitchell BS, Stone RM, Stopeck AT, Larson RA

Blood 100 (suppl 1):743, 2002

Published Date 12/20/2002

Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia: final analysis of CALGB 19802


Blood 106(11):1833, 2005

Published Date 11/15/2005

Intensified daunorubicin during induction and post-remission therapy of adult acute lymphoblastic leukemia (ALL): results of CALGB 19802


Blood 102 (11):#1375, 2003

Published Date 11/16/2003

Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Phase II Trial of Dose Intensification of Daunorubicin and Cytarabine Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradiation


Blood 98:2472, 2001

Published Date 11/1/2001

Relationships of response to oral topotecan for myelodysplastic syndrome with IPSS group and cytogenetics


Blood 100(suppl 1):3137, 2002

Published Date 12/20/2002

Oral topotecan for myelodysplastic syndrome (MDS) 2 schedules


Proc ASCO 20:1209, 2001

Published Date 5/1/2001

A phase II study of homoharringtonine in combination with low-dose cytarabine via continuous IV infusion for newly diagnosed patients with chronic myeloid leukemia: CALGB 19804


Blood 100 (suppl 1):3101, 2002

Published Date 12/20/2002

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or one-hour bolus infusion: results from CALGB 19805


Published Date 6/1/2005

Sequential phase II studies of flavopiridol by 72-hour continuous infusion and one-hour intravenous bolus for the treatment of relapsed B-cell chronic lymphocytic leukemia: results from CALGB 19805


Blood 104(11):3485, 2004

Published Date 12/1/2004
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
<th>Journal</th>
<th>Publication Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease</td>
<td>Rai KR, Byrd JC, Peterson BL, Larson RA</td>
<td>Blood 100 (suppl 1):772, 2002</td>
<td>Published Date 12/20/2002</td>
</tr>
<tr>
<td>2005</td>
<td>Blood and bone marrow are equivalent for real time RT-PCR monitoring of BCR/ABL transcripts in patients receiving treatment for Chronic Myelogenous Leukemia: A Cancer and Leukemia Group B Study (CALGB 29801)</td>
<td>Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD</td>
<td>International Journal of Oncology.</td>
<td>Accepted Date 12/2/2005</td>
</tr>
</tbody>
</table>
A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC) CALGB 30103
Rudin CM, Salgia R, Wang X, Vokes EE, Green MR
Proc ASCO:7168, 2005
Published Date 5/16/2005

A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104
Proc ASCO:7161, 2005
Published Date 5/16/2005

Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): a Cancer and Leukemia Group B (CALGB 30105) randomized phase II trial
Blackstock AW, Socinski MA, Rosenman J, Gu L, Wang X, Bogart JA, Vokes EE, Green MR
Proc ASCO:7060, 2005
Published Date 5/16/2005

Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): a CALGB stratified phase II trial
Ready N, Herndon JE, Vokes EE, Bogart JA, Crawford J, DiPetrillo T, Green MR
Proc ASCO:7078, 2004
Published Date 5/1/2004

Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)
Jahan TM, Gu L, Wang X, Kratzke RA, Green MR, Vokes EE, Kindler HL
Lung Cancer 49(suppl 2):S222, P-403, 2005
Published Date 7/4/2005

A phase II NCCTG/CALGB trial of imatinib (STI571) in patients with c-kit expressing relapsed small cell lung cancer: N0124/C30201
Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Morton RF, Schild SE, Jett JR, Adjei A
Annals of Oncology 16:1811-1816, 2005
Published Date 11/15/2005

A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit expressing relapsed small cell lung cancer: N0124/C30201
Adjei A, Mandrekar S, Dy GK, Bot B, Miller AA
Proc ASCO:7048, 2005
Published Date 5/16/2005

Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial
Vokes EE, Herndon JE, Kelley MJ, Watson DM, Cicchetti MG, Green MR
Proc ASCO:7005, 2004
Published Date 5/15/2004

A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC)
Tothy PK, Mauer AM, Haraf D, Rudin CM, Hoffman PC, Ferguson MK, Szeto L, Vokes EE
Proc ASCO:7170, 2004
Published Date 5/1/2004
Feasibility of video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer: Results of CALGB 39802
Swanson S, Herndon J, D'Amico A, Demmy T, McKenna R, Green M, Sugarbaker D
Proc ASCO 21:1158, 2002
Published Date 4/15/2002

Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): results of CALGB 39803
Jaklitsch MT, Gu L, Harpole DH, D'Amico TA, McKenna RJ, Krasna MJ, Kohman LJ, Swanson SJ, DeCamp MM, Sugarbaker DJ
Proc ASCO 7065, 2005
Published Date 5/16/2005

A phase II trial of 6-hydroxymethylacyfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer
Sherman CA, Herndon JE, Watson DM, Green MR
Lung Cancer 45(3):387-392, 2004
Published Date 9/23/2004

Capecitabine (xeloda) in malignant mesothelioma: a phase II trial by the CALGB
Otterson GA, Herndon JE, Watson D, Green MR, Kindler HL
Lung Cancer 44(2):251-259, 2004
Published Date 5/1/2004

Capecitabine (Xeloda) in malignant mesothelioma: a phase II trial by the CALGB
Proc ASCO abstract #2778, 2003
Published Date 5/31/2003

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited stage small cell lung cancer (L-SCLC): preliminary analysis of CALGB 39808
Int'l Jnl Rad Onc, Biol & Phys 59(2):460-468, 2004
Published Date 6/1/2004

70 Gy Thoracic Radiotherapy (TRT) concurrent with Cycle 3 of chemotherapy is feasible for Limited Stage Small Cell Lung Cancer (L-SCLC): Preliminary analysis of CALGB 39808
Published Date 5/2/2002

Spinal cord dose in limited stage small cell lung cancer: a preliminary quality assurance review committee (QARC) report on CALGB 39808 using target thoracic radiotherapy (TRT) doses of 60-70 Gy
Cicchetti MG, Bogart JA, Lyss AP, Turrisi AT, Green M, Herndon JE
Published Date 11/1/2001

Phase II study of Topotecan (Topo) + paclitaxel (tax) + G-CSF induction followed by concurrent chemoradiotherapy (CCRT) for patients (pts) with limited stage small cell lung cancer (L-SCLC): Preliminary analysis for CALGB 39808
Lyss AP, Herndon JE, Bogart JA, Watson DM, Turrisi AT, Green MR
Proc ASCO 20:1270, 2001
Published Date 5/1/2001

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
Annals of Oncology 15:410-418, 2004
Published Date 3/30/2004

Randomized Phase II Trial of Gemcitabine/Irinotecan and Gemcitabine/Docetaxel in Stage IIIB (Malignant Pleural Effusion) or Stage IV NSCLC: CALGB 39809
Lima CM, Lee H, Riczi NA, Herndon JE, Zhang K, Crawford J, King GW, Green MR
Proc ASCO 21:1344, 2002
Published Date 4/24/2003


Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (SLL): CALGB study 50002 Grinblatt DL, Johnson JL, Niedzwiecki D, Rizzieri DA, Bartlett NL, Cheson BD Blood 104(11):3284, 2004 Published Date 12/1/2004

Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103 Wilson WH, Niedzwiecki D, Zelenetz AD, Hurd DD, Porcu P, Martin E, Czuczman MS, Cheson BD, Canellos GP Proc ASCO:6530, 2005 Published Date 5/16/2005

A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: preliminary results of CALGB 59804 Bartlett N, Niedzwiecki D, Johnson J, Friedberg JW, Zelenetz AD, Canellos GP Proc ASCO abstract #2275, 2003 Published Date 5/31/2003


Increased mortality associated with the cyclophosphamide 1000 mg/m2 & Fludarabine 20 mg/m2 qd x 5 (CF) arm in patients with low grade lymphoma treated on E1496/CALGB 59902 Hochster H, Weller E, Kunzel T, Canellos G, Gray R, Horning S Proc ASCO 21:1125, 2002 Published Date 5/2/2002
Sequential doxorubicin and topotecan in relapsed/refractory aggressive NHL: results of CALGB 59906
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos GP, Cheson BD, Bartlett NL
Leukemia and Lymphoma, Accepted Date 1/13/2006

Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: results of CALGB 59906, a phase II study of doxorubicin and topotecan
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos GP, Cheson BD, Bartlett NL
Blood 104(11):2500, 2004

Eradication of minimal residual disease during treatment of mantle cell lymphoma: CALGB 59909
Sher DA, Johnson JL, Siddiqui M, Damon L, Linker C, Cheson BD, Stock W
Blood 104(11):1652, 2004

Intense immunochemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients with mantle cell lymphoma (MCL): CALGB 59909
Damon L, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Kelly M, Linker C, Canellos GP
Blood 104(11):895, 2004

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole (CAI) in renal cell carcinoma (CALGB 69901)
Stadler WM, Rosner GL, Small EJ, Hollis DR, Rini B, Zaentz D, Mahoney JF, Ratain MJ
Journal of Clinical Oncology 23(16):3726-3732, 2005

Successful implementation of the randomized discontinuation trial design to assess disease stabilization in renal cell carcinoma patients treated with the putative antiangiogenic agent carboxyaminoimidazole: A CALGB study
Stadler WM, Rosner G, Rini B, Hollis D, Small EJ, Ratain MJ
Proc ASCO abstract #773, 2003

Randomized discontinuation design: application to cytostatic antineoplastic agents
Rosner G, Stadler W, Ratain MJ
Journal of Clinical Oncology 20 (22):4478-4484, 2002

Economic outcomes of breast cancer survivorship: CALGB 79804
Hensley ML, Dowell J, Herrndon JE, Winer E, Stark N, Weeks JC, Paskett E
Breast Cancer Research and Treatment 91(2):153-161, 2005

Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of CALGB 80001
Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JW, Bem J, Mayer RJ, Bertagnolli MM

Sentinel node staging of resectable colon cancer: results of CALGB 80001 a multicenter study

Sentinel node staging of resectable colon cancer: results of CALGB 80001
Proc ASCO:3506, 2004
A phase II trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced non-metastatic pancreatic adenocarcinoma: preliminary analysis of CALGB 80003
Mamon H, Niedzwiecki D, Hollis DR, Tan BR, Smith JL, Blackstock AW, Tepper JE, Goldberg RM, Mayer RJ, Fuchs CS
International Journal of Radiation Oncology, Biology, Physics 63 suppl.1:S13, 2005
Published Date 12/1/2005

Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: intergroup S0033 (CALGB 80004) early results
Published Date 5/1/2002

A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland SL, Goldberg RM
Clinical Colorectal Cancer 5:292-294, 2005
Published Date 12/25/2005

Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803
Fuchs CS, Meyerhardt JA, Brady DL, Niedzwiecki D, Hollis DR, Chan AT, Saltz LB, Schilsky RL, Mayer RJ
Proc ASCO:3530, 2005
Published Date 5/16/2005

The impact of physical activity on patients with stage III colon cancer: findings from intergroup trial CALGB 89803
Meyerhardt JA, Brady DL, Niedzwiecki D, Hollis DR, Saltz LB, Willett WC, Mayer RJ, Schilsky RL, Fuchs CS
Proc ASCO:3534, 2005
Published Date 5/16/2005

Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial/CALGB 89803)
Proc ASCO:3500, 2004
Published Date 5/1/2004

Cost-effectiveness projections of FOLFOX vs IFL in first-line therapy of metastatic colorectal cancer
Hillner BE, Schrag D, Sargent DJ, Morton R, Fuchs CS, Goldberg RM
Cancer 104:1871-1884, 2005
Published Date 9/21/2005

A pooled analysis to assess safety and efficacy of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly patients with colorectal cancer
Sargent D, Goldberg RM, Bleiberg H, deGlamont A, Tournigand C, Andre T, Rothenberg ML, Green E, Mounedji-Boudiaf L, Tabah-Fisch I
7th World Congress on Gastrointestinal Cancer, 2005
Published Date 6/15/2005

Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
Meyerhardt JA, Sloan JA, Zhao X, Pollak M, Sargent DJ, Goldberg RM, Fuchs CS
Cancer Epidemiology, Biomarkers & Prevention 14(6):1402-1410, 2005
Published Date 6/14/2005

Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity
Grothey A, McLeod HL, Green EM, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson S, Findlay B, Goldberg RM
ASCO 23:248s#3509, 2005
Published Date 5/16/2005

Cost effectiveness projections of FOLFOX vs IFL in first-line therapy of metastatic colorectal cancer in the context of the US healthcare system
Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM
ASCO 23:253s, 2005
Published Date 5/16/2005

A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer
Morton RF, Sloan JA, Grothey A, Sargent DJ, McLeod HL, Green EM, Fuchs CS, Ramanathan RK, Williamson SK, Goldberg RM
ASCO 23:750s, 2005
Published Date 5/16/2005
Chemotherapy permits resection of metastatic colorectal cancer: experience from intergroup N9741
Delamont T, Krook J, Sargent DJ, Green E, Alberts SR, Fuchs CS
Annals of Oncology 16(3):425-429, 2005
Published Date 3/3/2005

Detailed analysis of oxaliplatin-associated neurotoxicity in intergroup trial N9741
Green EM, Sargent DJ, Goldberg RM, Grothey A
Proc Gastrointestinal Cancers Symposium:182, 2005
Published Date 1/27/2005

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from intergroup N9741
Dy GK, Krook J, Green EM, Sargent DJ, Alberts S, Pitot H, Morton R, Goldberg RM
Proc Gastrointestinal Cancers Symposium:185, 2005
Published Date 1/27/2005

Cost-effectiveness projections of FOLFOX vs IFL in first-line therapy of metastatic colorectal cancer
Hillner BE, Schrag D, Sargent DJ, Goldberg RM
Proc Gastrointestinal Cancers Symposium:187, 2005
Published Date 1/27/2005

Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): results from intergroup trial N9741
Fuchs CS, Pollak M, Sargent DJ, Meyerhardt JA, Ramanathan RK, Williamson S, Findlay B, Green E, Goldberg RM
Proc ASCO:3521, 2004
Published Date 5/1/2004

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR
Published Date 4/1/2004

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup trial N9741
Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA
Cancer 101(10):2170-2176, 2004
Published Date 4/1/2004

Oxaliplatin or CPT-11 + 5-fluorouracil/leucovorin or oxal + CPT-11 in advanced colorectal cancer: initial toxicity and response data from GI intergroup study N9741 (CALGB 89804)
Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP
Proc ASCO 21:511, 2002
Published Date 5/1/2002

Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
Published Date 4/1/2004

Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
Published Date 11/1/2001

Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
Proc ASCO 20:627, 2001
Published Date 5/1/2001

A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901
Ryan DP, Niedzwiecki D, Hollis DR, Miedema BW, Wadler S, Tepper JE, Mayer RJ
Proc ASCO:3560, 2004
Published Date 5/1/2004
Phase II trial of 5-fluorouracil, leucovorin, oxaliplatin and herceptin for patients with metastatic colorectal cancer refractory to initial therapy
Clark JW
Proc ASCO abstract #3584, 2003
Published Date 5/31/2003

A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904)
Kalke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ
Proc ASCO:4011, 2004
Published Date 5/1/2004

CALGB 90003: Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: an intergroup phase II study
Biology of Blood and Marrow Transplantation, Accepted Date 3/29/2006

A phase II Study of estramustine (E), docetaxel (D) and exisulind in hormone-refractory prostate cancer (HRPC): initial results of CALGB 90004
Dawson NA, Halabi S, Biggs DD, Ou S, Kelly WK, Small EJ
Proc ASCO:4649, 2005
Published Date 5/16/2005

The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006
Picus J, Halabi S, Vogelzang NJ, Kaplan EB, Kelly W, Small EJ
Proc ASCO abstract #1578, 2003
Published Date 5/31/2003

A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B 90008
Stadler WM, Halabi S, Ernstoff MS, Barrier R, Davila E, Picus J, Small EJ
Proc ASCO:4515, 2004
Published Date 5/1/2004

Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: results of CALGB 90102
Philips GK, Halabi S, Sanford BL, Bajorin DF, Small EJ
Proc ASCO:4540, 2004
Published Date 5/1/2004

CALGB 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-VEGF antibody (bevacizumab, Avastin®) in metastatic renal cell carcinoma
Rini BI, Halabi S, Taylor JR, Small EJ, Schilsky RL
Clinical Cancer Research 10(8):2584-2586, 2004
Published Date 4/15/2004
A phase II study of estramustine, docetaxel and carboplatin with granulocyte-colony stimulating factor support in patients with hormone-refractory prostate cancer (CALGB 99813)

Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ
Cancer 98(12):2592-2598, 2003

99813

A phase II study of estramustine, docetaxel, carboplatin (EDC) with G-CSF support in men with hormone refractory prostate cancer: CALGB 99813

Oh WK, Halabi S, Kelly WK, Godley PA, Werner C, Kantoff PW, Vogelzang NJ, Small EJ
Proc ASCO 21:779, 2002

99908

Telephone monitoring: early identification of psychological, physical and social distress in advanced stage cancer patients 65 or more years old

Kornblith AB, Dowell JM, Herndon JE, Rosenberg S, Engelman B, Small EJ, Morrison VA, Atkins JN, Muss HB, Holland JC
American Psychosocial Oncology Society, 2006

119801

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metatstatic, hormone refractory prostate cancer

Amin A, Halabi S, Werner CP, Small EJ, Studler WM, Gelmann EP
Urologic Oncology 22(5):398-403, 2004

99901

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium (E4897/C99908)

Cancer 100(8):1639-1645, 2004

150105

Correlation of clinical response to imatinib mesylate (IM) and tumor genotype in patients treated with IM for metastatic GI stromal tumors (GISTs)

Heinrich MC, Shoemaker JS, Corless CL, Hollis DR, Demetri GD, Bertagnolli MM, Fletcher JA
Proc ASCO 23:7, 2005

309801

Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score

Grunbert SM, Srivastava A, Grunberg KJ, Weeks J
Support Care Cancer 10:624-629, 2002

360001

Improving accrual of older persons to cancer treatment trials: a randomized trial of the Cancer and Leukemia Group B comparing an educational intervention with standard information

Kimmick GG, Kornblith AB, Mandelblatt J, Peterson BL, Johnson JL, Wheeler JD, Heinze RV, Cohen HJ, Muss HB
Journal of Clinical Oncology 23(10):2201-2207, 2005

360001

A randomized controlled trial of an educational program to improve accrual of older persons to cancer treatment protocols: CALGB 360001

Kimmick GG, Kornblith AB, Mandelblatt J, Peterson BL, Johnson JL, Wheeler JD, Cohen HJ, Muss HB
Proc ASCO:8040, 2004
High dose interferon Alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
Kirkwood JM, Ibrahim J, Sosman JA, Sondak VK, Agarwala SS, Ernstoff M, Rao U
Journal of Clinical Oncology 19(9):2370-2380, 2001

Phase II study of g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: CALGB 509901
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Zhang Z, Houghton AN, Haluska FG